[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_f49a772a-5bcb-4881-8011-8ac0b5cbcf60":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:f49a772a-5bcb-4881-8011-8ac0b5cbcf60,\"}":158},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":47,"indexDatabases":70,"url":20,"thumbnailPath":20,"statistic":111,"gsStatistic":20,"type":157,"analyzePriority":20},"f49a772a-5bcb-4881-8011-8ac0b5cbcf60","2024-04-07T07:34:57.912+00:00","2026-03-24T03:57:40.782+00:00",[],"BMC-Cancer",{"issn":12,"title":14,"url":16},{"VOID":13},"14712407",{"EN":15},"BMC Cancer",{"VOID":17},"https:\u002F\u002Flink.springer.com\u002Fjournal\u002F12885","PUBLISHER","PENDING",null,0,[23,31,39],{"id":24,"createTime":25,"updateTime":26,"relativeEntities":27,"label":28,"description":30,"parentId":20,"standard":20,"scholarHubFieldId":20},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":29},"Oncology",{},{"id":32,"createTime":33,"updateTime":34,"relativeEntities":35,"label":36,"description":38,"parentId":20,"standard":20,"scholarHubFieldId":20},"740fbbd4-0204-4499-bc5d-be3ba61fc9be","2023-05-29T10:24:05.032+00:00","2023-11-21T05:08:37.653+00:00",[],{"EN":37},"Cancer Research",{},{"id":40,"createTime":41,"updateTime":42,"relativeEntities":43,"label":44,"description":46,"parentId":20,"standard":20,"scholarHubFieldId":20},"5815288e-6c9a-443e-9993-d3989541283b","2023-05-29T10:24:27.336+00:00","2023-11-21T07:15:31.374+00:00",[],{"EN":45},"Genetics",{},[48,59],{"id":49,"createTime":50,"updateTime":51,"relativeEntities":52,"slug":53,"properties":54,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":57,"url":20,"parentIds":58,"statistic":20},"67883518-0c98-470e-b6b0-160ab49bb03d","2023-05-29T12:06:59.969+00:00","2024-02-19T18:45:45.100+00:00",[],"BMC",{"title":55},{"EN":53},"AFFILIATION",9,[],{"id":60,"createTime":61,"updateTime":62,"relativeEntities":63,"slug":64,"properties":65,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":68,"url":20,"parentIds":69,"statistic":20},"c5894808-4e99-4047-bbce-594f58821845","2023-05-29T10:24:08.212+00:00","2025-11-21T10:07:05.787+00:00",[],"BioMed-Central-Ltd-",{"title":66},{"EN":67},"BioMed Central Ltd.",10,[],[71,90],{"id":72,"indexDatabase":73,"url":87,"indexYears":20,"academicFieldIds":88,"indexDatabaseRanking":20},"04cd376c-5a10-450c-90ac-f2749a8e8524",{"id":74,"createTime":75,"updateTime":76,"relativeEntities":77,"label":78,"description":80,"key":83,"publicationTags":84,"standard":20},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":79,"VI":79},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":81,"EN":82},"Cơ sở dữ liệu SCIE","SCIE database","scie",[85,86],"SCIE","ISI","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002Fnull",[89],"248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":91,"indexDatabase":92,"url":104,"indexYears":105,"academicFieldIds":106,"indexDatabaseRanking":110},"3d430c67-a241-479c-9da0-2ea29c6fe2c9",{"id":93,"createTime":94,"updateTime":95,"relativeEntities":96,"label":97,"description":99,"key":101,"publicationTags":102,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":98,"VI":98},"Scopus - Elsevier",{"EN":98,"VI":100},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[103],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F28747","2001-2025",[107,108,109],"8d793241-fb62-4735-9243-df74a7813046","ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q1",{"impactFactor":21,"impactFactorByYear":112,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":117,"totalCitation":142,"totalCitationByYear":143,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":150,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},0.01,6,1,8724,{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},11,20,17,55,93,147,144,220,258,375,281,341,298,531,547,508,456,700,690,647,744,726,691,223,256,{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},70,35,21,24,15,0.03,{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},0.48,0.16,0.04,0.14,0.02,7,"JOURNAL",{"meta":159,"data":161},{"total":160},"11111",[162,300,457,751,989,1205,1365,1482,1663,1933],{"id":163,"createTime":164,"updateTime":165,"relativeEntities":166,"slug":167,"properties":168,"entityType":177,"verifyStatus":178,"verifyTime":165,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":180,"fullTextUrl":20,"authors":181,"publicationType":262,"publisherRelationship":263,"citationCount":20,"citationInfo":20,"publishDate":297,"publishYear":298,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"6508b377-0a27-435c-b543-8e63cb0bb9fc","2023-12-28T08:06:22.901+00:00","2025-02-26T23:59:48.604+00:00",[],"Long-term-mortality-among-women-with-epithelial-ovarian-cancer-a-population-based-study-in-British-Columbia-Canada",{"references":169,"abstract":171,"title":173,"doi":175},{"VOID":170},"Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014 - Special Topic: Skin Cancers. Canadian Cancer Society; 2014. http:\u002F\u002Fwww.cancer.ca\u002F. Accessed 20 May 2017.\nCanadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2016 - Special topic: HPV-associated cancers; 2016. http:\u002F\u002Fwww.cancer.ca\u002F. Accessed 20 May 2017.\nNuttall R. Canadian cancer statistics 2017. Canadian Cancer Society; 2017. http:\u002F\u002Fwww.cancer.ca\u002F. Accessed 20 July 2017.\nGérvas J. Ovarian cancer screening: could you recommend it? No. EBM 2016; doi: https:\u002F\u002Fdoi.org\u002F10.1136\u002Febmed-2016-110385.\nDinkelspiel HE, Champer M, Hou J, et al. Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 2015. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2015.06.005.\nColzani E, Liljegren A, Johansson ALV, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. JOC 2011; doi: https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2010.32.6462.\nVan Hemelrijck M, Folkvaljon Y, Adolfsson J, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fbju.13059.\nMassa ST, Osazuwa-Peters N, Christopher KM, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.oraloncology.2016.12.006.\nJanssen-Heijnen MLG, van Erning FN, De Ruysscher DK, Coebergh JWW, Groen HJM. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdv061.\nWebb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.bpobgyn.2016.08.006.\nKommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. Br J Cancer. 2016. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fbjc.2016.273.\nMatz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2016.10.019.\nMatz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2016.11.019.\nGilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.humpath.2008.01.003.\nKöbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pmed.0050232.\nBC cancer agency registry data (2011). Population data BC. BC cancer agency. 2011 http:\u002F\u002Fwww.popdata.bc.ca\u002Fdata. Accessed 20 May 2017.\nBC Vital Statistics Agency (2011). Vital statistics deaths. Population data BC BC vital statistics agency (2011). http:\u002F\u002Fwww.popdata.bc.ca\u002Fdata. Accessed 20 May 2017.\nBritish Columbia Ministry of Heath (2011): Consolidation file (MSP registration and premium billing). Population data BC MOH (2011). http:\u002F\u002Fwww.popdata.bc.ca\u002Fdata. Accessed 20 May 2017.\nHanley GE. Equity in the use and financing of medicines in British Columbia before and after the move to income-based pharma care. 2011. https:\u002F\u002Fopen.library.ubc.ca. Accessed 10 December 2017.\nAbout popdata. https:\u002F\u002Fwww.popdata.bc.ca\u002F. Accessed 16 April 2017.\nRStudio team (2016). RStudio: Integrated development for R. RStudio, inc., boston, MA URL http:\u002F\u002Fwww.rstudio.com\u002F. Accessed 17 May 2017.\nGangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer inBRCAMutation carriers. JAMA Surg. 2014. https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjamasurg.2014.1081.\nMcGee J, Giannakeas V, Karlan B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol. 2017. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2017.02.032.\nKotsopoulos J, Narod SA. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial? Expert Rev Anticancer Ther. 2018. https:\u002F\u002Fdoi.org\u002F10.1080\u002F14737140.2018.1424547.\nKöbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fhis.12349.\nVierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2014.07.100.\nSchrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. https:\u002F\u002Fdoi.org\u002F10.1097\u002FAOG.0b013e31825f3576.\nHanley GE, McAlpine JN, Miller D, et al. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer. 2018. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12885-018-4153-8.",{"EN":172},"Among women with epithelial ovarian cancer (EOC), histotype is one of the major prognostic factors. However, few data are available on histotype- specific survival and mortality estimates among these patients. We therefore examined survival and causes of death among women with EOC by histotype. A population- based cohort including all ovarian cancer patients diagnosed in British Columbia (BC) between 1990 and 2014 was built using population-based administrative datasets. We compared causes of death within histotypes, by age at diagnosis, BRCA status, and time since diagnosis. A total of 6975 women were identified as having been diagnosed with EOC between 1990 and 2014 in BC. The most common cause of death among these women was ovarian cancer until 10 years post diagnosis when other causes surpassed ovarian cancer as the leading cause of death. Among women with serous EOCs, ovarian cancer was the leading cause of death 12 years after diagnosis, whereas ovarian cancer was the leading cause of death for 8 years among women with non- serous EOCs. Among women with serous EOCs, ovarian cancer was the leading cause of death for 12 years among younger women (\u003C 60 years of age) compared to 8 years among women > = 60 years of age, and those with BRCA mutations were more likely to die from ovarian cancer than those without a BRCA mutation. Within 10 years from diagnosis, ovarian cancer is the leading cause of death among women diagnosed with EOC.",{"EN":174},"Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada",{"VOID":176},"10.1186\u002Fs12885-018-4970-9","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-018-4970-9",[182,209,222,238,250],{"id":183,"sortIndex":184,"researcher":20,"roles":185,"affiliations":187,"properties":206},"ff26ca80-67a8-4737-ab11-5c2d043f4a25",4,[186],"AUTHOR",[188,196],{"id":20,"sortIndex":21,"affiliation":189,"properties":20},{"id":190,"createTime":191,"updateTime":191,"relativeEntities":192,"slug":20,"properties":193,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"afa34d9f-ec7b-457a-84d0-2b607985c294","2024-01-04T05:34:03.580+00:00",[],{"title":194},{"VI":195},"Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, Canada",{"id":197,"sortIndex":115,"affiliation":198,"properties":205},"9582d196-b090-4e73-a237-c2bcb6f85479",{"id":199,"createTime":200,"updateTime":200,"relativeEntities":201,"slug":20,"properties":202,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"b27281de-2be7-4d41-912d-02e4242d89c2","2023-12-28T08:06:22.980+00:00",[],{"title":203},{"VI":204},"Diamond Health Care Center, Vancouver General Hospital, Vancouver, Canada",{},{"title":207},{"VI":208},"Gillian E. Hanley",{"id":210,"sortIndex":211,"researcher":20,"roles":212,"affiliations":213,"properties":219},"620a1591-6080-471f-bfde-9ab83d6688b4",2,[186],[214],{"id":20,"sortIndex":21,"affiliation":215,"properties":20},{"id":190,"createTime":191,"updateTime":191,"relativeEntities":216,"slug":20,"properties":217,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":218},{"VI":195},{"title":220},{"VI":221},"Jessica N. McAlpine",{"id":223,"sortIndex":224,"researcher":20,"roles":225,"affiliations":226,"properties":235},"e84836a1-a321-4002-a08a-74aba2069979",3,[186],[227],{"id":20,"sortIndex":21,"affiliation":228,"properties":20},{"id":229,"createTime":230,"updateTime":230,"relativeEntities":231,"slug":20,"properties":232,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"1c1db478-ac3e-435a-9522-ad0547fcafa3","2023-12-12T19:52:42.273+00:00",[],{"title":233},{"VI":234},"Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, Canada",{"title":236},{"VI":237},"Michael R. Law",{"id":239,"sortIndex":115,"researcher":20,"roles":240,"affiliations":241,"properties":247},"ececcba9-58e8-495d-9c1e-5e1c05d6485f",[186],[242],{"id":20,"sortIndex":21,"affiliation":243,"properties":20},{"id":190,"createTime":191,"updateTime":191,"relativeEntities":244,"slug":20,"properties":245,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":246},{"VI":195},{"title":248},{"VI":249},"Aline Talhouk",{"id":251,"sortIndex":21,"researcher":20,"roles":252,"affiliations":253,"properties":259},"8fcfb4c4-537e-4fa7-8999-09d066b4a6e2",[186],[254],{"id":20,"sortIndex":21,"affiliation":255,"properties":20},{"id":190,"createTime":191,"updateTime":191,"relativeEntities":256,"slug":20,"properties":257,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":258},{"VI":195},{"title":260},{"VI":261},"Nimisha Arora","ARTICLE",{"url":180,"publisher":264,"properties":292},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":265,"slug":10,"properties":266,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":270,"manageAffiliations":271,"indexDatabases":272,"url":20,"thumbnailPath":20,"statistic":287,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":267,"title":268,"url":269},{"VOID":13},{"EN":15},{"VOID":17},[],[],[273,280],{"id":72,"indexDatabase":274,"url":87,"indexYears":20,"academicFieldIds":279,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":275,"label":276,"description":277,"key":83,"publicationTags":278,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":281,"url":104,"indexYears":105,"academicFieldIds":286,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":282,"label":283,"description":284,"key":101,"publicationTags":285,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":288,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":289,"totalCitation":142,"totalCitationByYear":290,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":291,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":293,"pages":295},{"VOID":294},"18",{"VOID":296},"1-9","2018-10-25",2018,false,{"id":301,"createTime":302,"updateTime":302,"relativeEntities":303,"slug":20,"properties":304,"entityType":177,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":313,"fullTextUrl":20,"authors":314,"publicationType":262,"publisherRelationship":421,"citationCount":20,"citationInfo":20,"publishDate":455,"publishYear":456,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"c6816ed0-3e65-4deb-b96a-344f1a96a863","2024-02-15T23:59:42.979+00:00",[],{"references":305,"abstract":307,"title":309,"doi":311},{"VOID":306},"Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis. 2000, 21: 485-495. 10.1093\u002Fcarcin\u002F21.3.485.\nSchmitt CA, Lowe SW: Apoptosis and therapy. J Pathol. 1999, 187: 127-137. 10.1002\u002F(SICI)1096-9896(199901)187:1\u003C127::AID-PATH251>3.0.CO;2-T.\nOkada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004, 4: 592-603. 10.1038\u002Fnrc1412.\nHockel M, Schlenger K, Hockel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59: 4525-4528.\nImoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J: Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002, 62: 4860-4866.\nHakumaki JM, Kauppinen RA: 1H NMR visible lipids in the life and death of cells. Trends Biochem Sci. 2000, 25: 357-362. 10.1016\u002FS0968-0004(00)01614-5.\nRoss BD: The biochemistry of living tissues: examination by MRS. NMR Biomed. 1992, 5: 215-219.\nBlankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF: Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood. 1997, 89: 3778-3786.\nHakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA: 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med. 1999, 5: 1323-1327. 10.1038\u002F15279.\nCheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG: Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1997, 94: 6408-6413. 10.1073\u002Fpnas.94.12.6408.\nMahon MM, deSouza NM, Dina R, Soutter WP, McIndoe GA, Williams AD, Cox IJ: Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study. NMR Biomed. 2004, 17: 144-153. 10.1002\u002Fnbm.869.\nMillis K, Weybright P, Campbell N, Fletcher JA, Fletcher CD, Cory DG, Singer S: Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999, 41: 257-267. 10.1002\u002F(SICI)1522-2594(199902)41:2\u003C257::AID-MRM8>3.0.CO;2-N.\nSitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE, Gribbestad IS: Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA. 2004, 16: 174-181. 10.1007\u002Fs10334-003-0025-5.\nSitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006, 19: 30-40. 10.1002\u002Fnbm.992.\nSwanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J: Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI\u002F3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003, 50: 944-954. 10.1002\u002Fmrm.10614.\nSwanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J: Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006, 55: 1257-1264. 10.1002\u002Fmrm.20909.\nGriffin JL, Lehtimaki KK, Valonen PK, Grohn OH, Kettunen MI, Yla-Herttuala S, Pitkanen A, Nicholson JK, Kauppinen RA: Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res. 2003, 63: 3195-3201.\nGriffin JL, Blenkiron C, Valonen PK, Caldas C, Kauppinen RA: High-resolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma. Anal Chem. 2006, 78: 1546-1552. 10.1021\u002Fac051418o.\nLehtimaki KK, Valonen PK, Griffin JL, Vaisanen TH, Grohn OH, Kettunen MI, Vepsalainen J, Yla-Herttuala S, Nicholson J, Kauppinen RA: Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol Chem. 2003, 278: 45915-45923. 10.1074\u002Fjbc.M306209200.\nValonen PK, Griffin JL, Lehtimaki KK, Liimatainen T, Nicholson JK, Grohn OH, Kauppinen RA: High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed. 2005, 18: 252-259. 10.1002\u002Fnbm.955.\nLyng H, Sundfor K, Rofstad EK: Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int J Radiat Oncol Biol Phys. 2000, 46: 935-946. 10.1016\u002FS0360-3016(99)00497-6.\nForshed J, Schuppe-Koistinen I, Jacobsson SP: Peak alignment of NMR signals by means of genetic algorithm. Anal Chim Acta. 2003, 487: 189-199. 10.1016\u002FS0003-2670(03)00570-1.\nLee GC, Woodruff DL: Beam search for peak alignment of NMR signals. Anal Chim Acta. 2004, 513: 413-416. 10.1016\u002Fj.aca.2004.02.068.\nPodo F: Tumour phospholipid metabolism. NMR Biomed. 1999, 12: 413-439. 10.1002\u002F(SICI)1099-1492(199911)12:7\u003C413::AID-NBM587>3.0.CO;2-U.\nFoster DA, Xu L: Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003, 1: 789-800.\nAckerstaff E, Glunde K, Bhujwalla ZM: Choline phospholipid metabolism: A target in cancer cells?. J Cell Biochem. 2003, 90: 525-533. 10.1002\u002Fjcb.10659.\nStapleton PP, O'Flaherty L, Redmond HP, Bouchier-Hayes DJ: Host defense – a role for the amino acid taurine?. J Parenter Enteral Nutr. 1998, 22: 42-48.\nWalenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000, 60: 916-921.\nWalenta S, Mueller-Klieser WF: Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004, 14: 267-274. 10.1016\u002Fj.semradonc.2004.04.004.\nKuesel AC, Sutherland GR, Halliday W, Smith IC: 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994, 7: 149-155.\nThe pre-publication history for this paper can be accessed here:http:\u002F\u002Fwww.biomedcentral.com\u002F1471-2407\u002F7\u002F11\u002Fprepub",{"EN":308},"High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS) provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of the samples after spectra acquisition. Experimental studies have suggested that the method can be used for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density. Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition. The apoptotic cell density correlated with the standard pulse-acquire spectra (p \u003C 0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty acid -CH2 to CH3 (p = 0.02). In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p \u003C 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important. Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p \u003C 0.001). Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease.",{"EN":310},"Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas",{"VOID":312},"10.1186\u002F1471-2407-7-11","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002F1471-2407-7-11",[315,332,347,359,371,394,409],{"id":316,"sortIndex":114,"researcher":20,"roles":317,"affiliations":318,"properties":329},"59f9ac6a-3127-463b-a02c-6141b097714e",[186],[319],{"id":20,"sortIndex":21,"affiliation":320,"properties":20},{"id":321,"createTime":322,"updateTime":323,"relativeEntities":324,"slug":325,"properties":326,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"07ad7a3d-0e1a-48c4-a2f4-5acb76ec1c54","2024-01-04T21:28:35.030+00:00","2025-06-11T20:42:35.205+00:00",[],"Department-of-Circulation-and-Medical-Imaging-Norwegian-University-of-Science-and-Technology-Trondheim-Norway",{"title":327},{"VI":328},"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway",{"title":330},{"VI":331},"Ingrid S Gribbestad",{"id":333,"sortIndex":184,"researcher":20,"roles":334,"affiliations":335,"properties":344},"4c978b1f-86cf-4f58-9776-91ee2ec61dae",[186],[336],{"id":20,"sortIndex":21,"affiliation":337,"properties":20},{"id":338,"createTime":339,"updateTime":339,"relativeEntities":340,"slug":20,"properties":341,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"0fa12756-4b4e-4655-8498-0a0fb9ff0ab9","2023-12-13T04:54:51.900+00:00",[],{"title":342},{"VI":343},"Department of Gynecologic Oncology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway",{"title":345},{"VI":346},"Kolbein Sundfør",{"id":348,"sortIndex":211,"researcher":20,"roles":349,"affiliations":350,"properties":356},"99bd14f7-3317-4dd4-8c07-9947209628bd",[186],[351],{"id":20,"sortIndex":21,"affiliation":352,"properties":20},{"id":321,"createTime":322,"updateTime":323,"relativeEntities":353,"slug":325,"properties":354,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":355},{"VI":328},{"title":357},{"VI":358},"Tone F Bathen",{"id":360,"sortIndex":224,"researcher":20,"roles":361,"affiliations":362,"properties":368},"ba996abf-b255-475d-810f-fcddbee8ff88",[186],[363],{"id":20,"sortIndex":21,"affiliation":364,"properties":20},{"id":321,"createTime":322,"updateTime":323,"relativeEntities":365,"slug":325,"properties":366,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":367},{"VI":328},{"title":369},{"VI":370},"Line R Jensen",{"id":372,"sortIndex":373,"researcher":20,"roles":374,"affiliations":375,"properties":391},"867bca3c-bf5b-497d-853d-83843b5c50b3",5,[186],[376,381],{"id":20,"sortIndex":21,"affiliation":377,"properties":20},{"id":338,"createTime":339,"updateTime":339,"relativeEntities":378,"slug":20,"properties":379,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":380},{"VI":343},{"id":382,"sortIndex":115,"affiliation":383,"properties":390},"4f46ff60-c8e7-4106-9328-ca8b84c1ad09",{"id":384,"createTime":385,"updateTime":385,"relativeEntities":386,"slug":20,"properties":387,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"764bc2fe-ff02-4178-8410-cb86ba7fadab","2024-02-15T23:59:43.206+00:00",[],{"title":388},{"VI":389},"Department of Medical Informatics, University of Oslo, Oslo, Norway",{},{"title":392},{"VI":393},"Gunnar B Kristensen",{"id":395,"sortIndex":21,"researcher":20,"roles":396,"affiliations":397,"properties":406},"3938ae8c-2c24-41b0-a779-e7f7c511876b",[186],[398],{"id":20,"sortIndex":21,"affiliation":399,"properties":20},{"id":400,"createTime":401,"updateTime":401,"relativeEntities":402,"slug":20,"properties":403,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"c57a5094-4b62-4c7b-9a7c-0cc3a114b8af","2023-12-12T18:54:38.571+00:00",[],{"title":404},{"VI":405},"Department of Radiation Biology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway",{"title":407},{"VI":408},"Heidi Lyng",{"id":410,"sortIndex":115,"researcher":20,"roles":411,"affiliations":412,"properties":418},"7bbdfaf6-7a8a-4aec-9e96-06fef6af13cb",[186],[413],{"id":20,"sortIndex":21,"affiliation":414,"properties":20},{"id":321,"createTime":322,"updateTime":323,"relativeEntities":415,"slug":325,"properties":416,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":417},{"VI":328},{"title":419},{"VI":420},"Beathe Sitter",{"url":313,"publisher":422,"properties":450},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":423,"slug":10,"properties":424,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":20,"thumbnailPath":20,"statistic":445,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":425,"title":426,"url":427},{"VOID":13},{"EN":15},{"VOID":17},[],[],[431,438],{"id":72,"indexDatabase":432,"url":87,"indexYears":20,"academicFieldIds":437,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":433,"label":434,"description":435,"key":83,"publicationTags":436,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":439,"url":104,"indexYears":105,"academicFieldIds":444,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":440,"label":441,"description":442,"key":101,"publicationTags":443,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":446,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":447,"totalCitation":142,"totalCitationByYear":448,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":449,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":451,"pages":453},{"VOID":452},"7",{"VOID":454},"1-12","2007-01-17",2007,{"id":458,"createTime":459,"updateTime":460,"relativeEntities":461,"slug":462,"properties":463,"entityType":177,"verifyStatus":178,"verifyTime":460,"verifyNote":179,"syncStatus":19,"languages":479,"translateLanguages":20,"viewCount":21,"primaryUrl":481,"fullTextUrl":20,"authors":482,"publicationType":262,"publisherRelationship":615,"citationCount":649,"citationInfo":650,"publishDate":652,"publishYear":653,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":654,"isForceReanalyzing":299},"e2bc5022-1de0-4ac3-a195-85508afd3058","2024-04-17T16:47:37.591+00:00","2025-01-24T23:59:42.362+00:00",[],"Combining-tissue-and-circulating-tumor-DNA-increases-the-detection-rate-of-a-CTNNB1-mutation-in-hepatocellular-carcinoma",{"mag":464,"keywords":466,"pmc":467,"openalex":469,"abstract":471,"title":473,"pm":475,"doi":477},{"VOID":465},"3142287024",{},{"VOID":468},"8028749",{"VOID":470},"W3142287024",{"EN":472},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:sec>\n                \u003Cjats:title>Background and aims\u003C\u002Fjats:title>\n                \u003Cjats:p>Studies suggest that mutations in the \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of serial non-invasive mutational profiling of tumors. Combining tumor tissue and ctDNA analysis may increase the detection rate of mutations.\u003C\u002Fjats:p>\n                \u003Cjats:p>This study aimed to evaluate the frequency of the \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> p.T41A mutation in ctDNA and tumor samples from HCC patients and to evaluate the concordance rates between plasma and tissue. We further evaluated changes in ctDNA after various HCC treatment modalities and the impact of the \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> p.T41A mutation on the clinical course of HCC.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Methods\u003C\u002Fjats:title>\n                \u003Cjats:p>We used droplet digital PCR to analyze plasma from 95 patients and the corresponding tumor samples from 37 patients during 3 years follow up.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Results\u003C\u002Fjats:title>\n                \u003Cjats:p>In tumor tissue samples, the mutation rate was 8.1% (3\u002F37). In ctDNA from HCC patients, the \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> mutation rate was 9.5% (9\u002F95) in the pre-treatment samples. Adding results from plasma analysis to the subgroup of patients with available tissue samples, the mutation detection rate increased to 13.5% (5\u002F37). There was no difference in overall survival according to \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> mutational status. Serial testing of ctDNA suggested a possible clonal evolution of HCC or arising multicentric tumors with separate genetic profiles in individual patients.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Conclusion\u003C\u002Fjats:title>\n                \u003Cjats:p>Combining analysis of ctDNA and tumor tissue increased the detection rate of \u003Cjats:italic>CTNNB1\u003C\u002Fjats:italic> mutation in HCC patients. A liquid biopsy approach may be useful in a tailored therapy of HCC.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>",{"EN":474},"Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma",{"VOID":476},"33827453",{"VOID":478},"10.1186\u002Fs12885-021-08103-0",[480],"EN","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-021-08103-0",[483,505,527,547,564,579,596],{"id":484,"sortIndex":373,"researcher":20,"roles":485,"affiliations":486,"properties":498},"a289ec85-8232-43ad-9072-bb7a1a9c8b60",[],[487],{"id":488,"sortIndex":21,"affiliation":489,"properties":20},"92799783-a12f-49d5-a698-85c31ee70f9c",{"id":490,"createTime":491,"updateTime":492,"relativeEntities":493,"slug":494,"properties":495,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"a0e959e3-7388-4ea3-8487-d35ca83906c9","2024-01-04T03:04:37.298+00:00","2024-12-10T20:11:29.811+00:00",[],"Department-of-Clinical-Biochemistry-Aarhus-University-Hospital-Aarhus-Denmark",{"title":496},{"VI":497},"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark",{"openalex":499,"orcid":501,"title":503},{"VOID":500},"A5052845137",{"VOID":502},"https:\u002F\u002Forcid.org\u002F0000-0002-9472-8099",{"EN":504},"Boe Sandahl Sørensen",{"id":506,"sortIndex":184,"researcher":20,"roles":507,"affiliations":508,"properties":520},"7a9f7f37-c0a7-4140-8089-ca7ee7d239e7",[],[509],{"id":510,"sortIndex":21,"affiliation":511,"properties":20},"a2dc7943-169c-4e63-9c90-7912e12c1c28",{"id":512,"createTime":513,"updateTime":514,"relativeEntities":515,"slug":516,"properties":517,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"bce09ff1-3228-4f72-83e6-cacf0ed29c69","2023-12-30T00:22:19.027+00:00","2024-12-01T06:13:34.949+00:00",[],"Department-of-Pathology-Aarhus-University-Hospital-Aarhus-Denmark",{"title":518},{"VI":519},"Department of Pathology, Aarhus University Hospital, Aarhus, Denmark",{"openalex":521,"orcid":523,"title":525},{"VOID":522},"A5078293062",{"VOID":524},"https:\u002F\u002Forcid.org\u002F0000-0003-2158-3885",{"EN":526},"Stephen Hamilton-Dutoit",{"id":528,"sortIndex":114,"researcher":20,"roles":529,"affiliations":530,"properties":542},"aabee03e-d6d6-451c-901e-4edb03da3a1b",[],[531],{"id":532,"sortIndex":21,"affiliation":533,"properties":20},"d7c47765-e4ac-4270-bac0-950d7c4ab93e",{"id":534,"createTime":535,"updateTime":536,"relativeEntities":537,"slug":538,"properties":539,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"193a4c06-d087-40c6-831c-a9ca230ef9b1","2024-01-12T01:06:02.604+00:00","2024-10-01T16:46:29.904+00:00",[],"Department-of-Hepatology-and-Gastroenterology-Aarhus-University-Hospital-Aarhus-Denmark",{"title":540},{"VI":541},"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark",{"openalex":543,"title":545},{"VOID":544},"A5089518876",{"EN":546},"Jens Kelsen",{"id":548,"sortIndex":224,"researcher":20,"roles":549,"affiliations":550,"properties":557},"e1298237-fdfe-461e-ac03-8eb6c5315ace",[],[551],{"id":552,"sortIndex":21,"affiliation":553,"properties":20},"209449e1-e703-4b75-b843-89d9e86fcbbf",{"id":534,"createTime":535,"updateTime":536,"relativeEntities":554,"slug":538,"properties":555,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":556},{"VI":541},{"openalex":558,"orcid":560,"title":562},{"VOID":559},"A5083375223",{"VOID":561},"https:\u002F\u002Forcid.org\u002F0000-0001-8998-7910",{"EN":563},"Henning Grønbæk",{"id":565,"sortIndex":115,"researcher":20,"roles":566,"affiliations":567,"properties":574},"a7c988ce-6219-437e-af24-719a246e0fcc",[],[568],{"id":569,"sortIndex":21,"affiliation":570,"properties":20},"08af5d9c-cb73-41f5-9d63-e32dff59a52b",{"id":490,"createTime":491,"updateTime":492,"relativeEntities":571,"slug":494,"properties":572,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":573},{"VI":497},{"openalex":575,"title":577},{"VOID":576},"A5060557816",{"EN":578},"Michelle Simone Clement",{"id":580,"sortIndex":21,"researcher":20,"roles":581,"affiliations":582,"properties":589},"79eb5b2a-77eb-43c5-8c59-51aa7efe2425",[],[583],{"id":584,"sortIndex":21,"affiliation":585,"properties":20},"240a7a06-e142-4421-97dc-50e0bba3f0ce",{"id":534,"createTime":535,"updateTime":536,"relativeEntities":586,"slug":538,"properties":587,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":588},{"VI":541},{"openalex":590,"orcid":592,"title":594},{"VOID":591},"A5026013542",{"VOID":593},"https:\u002F\u002Forcid.org\u002F0000-0001-9762-1679",{"EN":595},"Stine Karlsen",{"id":597,"sortIndex":211,"researcher":20,"roles":598,"affiliations":599,"properties":610},"eadf2cdb-75db-4279-a933-3d0077e2b1fe",[],[600],{"id":601,"sortIndex":21,"affiliation":602,"properties":20},"a70e2efd-e88f-4777-a3ac-42b0934151a2",{"id":603,"createTime":604,"updateTime":604,"relativeEntities":605,"slug":606,"properties":607,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"a3a74469-a568-49d4-9881-aebdbdc0fc89","2024-04-17T16:47:37.636+00:00",[],"Department-of-Clinical-Oncology-and-Danish-Centre-of-Particle-Therapy-Aarhus-University-Hospital-Aarhus-Denmark",{"title":608},{"EN":609},"Department of Clinical Oncology and Danish Centre of Particle Therapy, Aarhus University Hospital, Aarhus, Denmark",{"openalex":611,"title":613},{"VOID":612},"A5023373846",{"EN":614},"Britta Weber",{"url":20,"publisher":616,"properties":644},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":617,"slug":10,"properties":618,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":622,"manageAffiliations":623,"indexDatabases":624,"url":20,"thumbnailPath":20,"statistic":639,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":619,"title":620,"url":621},{"VOID":13},{"EN":15},{"VOID":17},[],[],[625,632],{"id":72,"indexDatabase":626,"url":87,"indexYears":20,"academicFieldIds":631,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":627,"label":628,"description":629,"key":83,"publicationTags":630,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":633,"url":104,"indexYears":105,"academicFieldIds":638,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":634,"label":635,"description":636,"key":101,"publicationTags":637,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":640,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":641,"totalCitation":142,"totalCitationByYear":642,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":643,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":645,"issue":647},{"VOID":646},"21",{"VOID":648},"1",8,{"total":649,"publishYear":20,"statisticByYear":651},{"2021":211,"2022":224,"2023":224},"2021-12-01",2021,[655,659,663,667,671,675,679,683,687,691,695,699,703,707,711,715,719,723,727,731,735,739,743,747],{"id":20,"text":656,"url":20,"identifiers":657},"Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–79. https:\u002F\u002Fdoi.org\u002F10.1586\u002F17474124.2015.1028363.",{"doi":658},"10.1586\u002F17474124.2015.1028363",{"id":20,"text":660,"url":20,"identifiers":661},"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa0708857.",{"doi":662},"10.1056\u002FNEJMoa0708857",{"id":20,"text":664,"url":20,"identifiers":665},"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0140-6736(16)32453-9.",{"doi":666},"10.1016\u002Fs0140-6736(16)32453-9",{"id":20,"text":668,"url":20,"identifiers":669},"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1915745.",{"doi":670},"10.1056\u002FNEJMoa1915745",{"id":20,"text":672,"url":20,"identifiers":673},"Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72(2):215–29. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2019.08.017.",{"doi":674},"10.1016\u002Fj.jhep.2019.08.017",{"id":20,"text":676,"url":20,"identifiers":677},"Lin DC, Mayakonda A, Dinh HQ, Huang P, Lin L, Liu X, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77(9):2255–65. https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-16-2822.",{"doi":678},"10.1158\u002F0008-5472.can-16-2822",{"id":20,"text":680,"url":20,"identifiers":681},"Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(3):220–9. https:\u002F\u002Fdoi.org\u002F10.3350\u002Fcmh.2015.21.3.220.",{"doi":682},"10.3350\u002Fcmh.2015.21.3.220",{"id":20,"text":684,"url":20,"identifiers":685},"Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018;9(4):5492–508. https:\u002F\u002Fdoi.org\u002F10.18632\u002Foncotarget.23695.",{"doi":686},"10.18632\u002Foncotarget.23695",{"id":20,"text":688,"url":20,"identifiers":689},"Rebouissou S, Franconi A, Calderaro J, Letouze E, Imbeaud S, Pilati C, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology. 2016;64(6):2047–61. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fhep.28638.",{"doi":690},"10.1002\u002Fhep.28638",{"id":20,"text":692,"url":20,"identifiers":693},"Vilarinho S, Erson-Omay EZ, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmanci AS, et al. Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. J Hepatol. 2017;67(1):186–91. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2017.03.009.",{"doi":694},"10.1016\u002Fj.jhep.2017.03.009",{"id":20,"text":696,"url":20,"identifiers":697},"Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, et al. Biomarkers associated with response to Regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156(6):1731–41. https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2019.01.261.",{"doi":698},"10.1053\u002Fj.gastro.2019.01.261",{"id":20,"text":700,"url":20,"identifiers":701},"Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116–26. https:\u002F\u002Fdoi.org\u002F10.1158\u002F1078-0432.ccr-18-2293.",{"doi":702},"10.1158\u002F1078-0432.ccr-18-2293",{"id":20,"text":704,"url":20,"identifiers":705},"Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, et al. beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–41. https:\u002F\u002Fdoi.org\u002F10.1158\u002F2159-8290.cd-19-0074.",{"doi":706},"10.1158\u002F2159-8290.cd-19-0074",{"id":20,"text":708,"url":20,"identifiers":709},"Perkins G, Lu H, Garlan F, Taly V. Droplet-based digital PCR: application in cancer research. Adv Clin Chem. 2017;79:43–91. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fbs.acc.2016.10.001.",{"doi":710},"10.1016\u002Fbs.acc.2016.10.001",{"id":20,"text":712,"url":20,"identifiers":713},"Milbury CA, Zhong Q, Lin J, Williams M, Olson J, Link DR, et al. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol Detect Quantif. 2014;1(1):8–22. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.bdq.2014.08.001.",{"doi":714},"10.1016\u002Fj.bdq.2014.08.001",{"id":20,"text":716,"url":20,"identifiers":717},"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jbi.2008.08.010.",{"doi":718},"10.1016\u002Fj.jbi.2008.08.010",{"id":20,"text":720,"url":20,"identifiers":721},"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jbi.2019.103208.",{"doi":722},"10.1016\u002Fj.jbi.2019.103208",{"id":20,"text":724,"url":20,"identifiers":725},"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41571-018-0073-4.",{"doi":726},"10.1038\u002Fs41571-018-0073-4",{"id":20,"text":728,"url":20,"identifiers":729},"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnature14404.",{"doi":730},"10.1038\u002Fnature14404",{"id":20,"text":732,"url":20,"identifiers":733},"Xiao Q, Wu J, Wang W-J, Chen S, Zheng Y, Yu X, et al. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018;24(3):262–70. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnm.4496.",{"doi":734},"10.1038\u002Fnm.4496",{"id":20,"text":736,"url":20,"identifiers":737},"Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152(4):880–94.e6. https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2016.11.042.",{"doi":738},"10.1053\u002Fj.gastro.2016.11.042",{"id":20,"text":740,"url":20,"identifiers":741},"Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–39.e4. https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2015.05.061.",{"doi":742},"10.1053\u002Fj.gastro.2015.05.061",{"id":20,"text":744,"url":20,"identifiers":745},"Letouze E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat Commun. 2017;8(1):1315. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41467-017-01358-x.",{"doi":746},"10.1038\u002Fs41467-017-01358-x",{"id":20,"text":748,"url":20,"identifiers":749},"Oversoe SK, Clement MS, Pedersen MH, Weber B, Aagaard NK, Villadsen GE, et al. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand J Gastroenterol. 2020;55(12):1–8. https:\u002F\u002Fdoi.org\u002F10.1080\u002F00365521.2020.1837928.",{"doi":750},"10.1080\u002F00365521.2020.1837928",{"id":752,"createTime":753,"updateTime":754,"relativeEntities":755,"slug":756,"properties":757,"entityType":177,"verifyStatus":178,"verifyTime":754,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":766,"fullTextUrl":20,"authors":767,"publicationType":262,"publisherRelationship":955,"citationCount":20,"citationInfo":20,"publishDate":988,"publishYear":298,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"4518b48c-c3a1-4a5c-b4a2-14fa3286b294","2023-12-19T07:42:09.037+00:00","2025-02-25T23:59:40.588+00:00",[],"Incidence-and-risk-factors-of-subsyndromal-delirium-after-curative-resection-of-gastric-cancer",{"references":758,"abstract":760,"title":762,"doi":764},{"VOID":759},"Inouye SK. Delirium in older persons. N Engl J Med. 2006;354:1157–65.\nDyer CB, Ashton CM, Teasdale TA. Postoperative delirium. A review of 80 primary data-collection studies. Arch Intern Med. 1995;155:461–5.\nZhu Y, Wang G, Liu S, Zhou S, Lian Y, Zhang C, et al. Risk factors for postoperative delirium in patients undergoing major head and neck cancer surgery: a meta-analysis. Jpn J Clin Oncol. 2017;47:505–11.\nMurakawa K, Kitamura Y, Watanabe S, Hongo S, Shinomiya K, Sendo T. Clinical risk factors associated with postoperative delirium and evaluation of delirium management and assessment team in lung and esophageal cancer patients. J Pharm Res Health Care. 2015;1:4.\nHasegawa T, Saito I, Takeda D, Iwata E, Yonezawa N, Kakei Y, et al. Risk factors associated with postoperative delirium after surgery for oral cancer. J Craniomaxillofac Surg. 2015;43:1094–8.\nYoshimura Y, Kubo S, Shirata K, Hirohashi K, Tanaka H, Shuto T, et al. Risk factors for postoperative delirium after liver resection for hepatocellular carcinoma. World J Surg. 2004;28:982–6.\nInouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911–22.\nCole MG, Primeau FJ, Elie LM. Delirium: prevention, treatment, and outcome studies. J Geriatr Psychiatry Neurol. 1998;11:126–37. discussion 157-8\nMarcantonio ER, Kiely DK, Simon SE, John Orav E, Jones RN, Murphy KM, et al. Outcomes of older people admitted to postacute facilities with delirium. J Am Geriatr Soc. 2005;53:963–9.\nLakatos BE, Capasso V, Mitchell MT, Kilroy SM, Lussier-Cushing M, Sumner L, et al. Falls in the general hospital: association with delirium, advanced age, and specific surgical procedures. Psychosomatics. 2009;50:218–26.\nFong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5:210–20.\nLevkoff SE, Liptzin B, Cleary PD, Wetle T, Evans DA, Rowe JW, et al. Subsyndromal Delirium. Am J Geriatr Psychiatry. 1996;4:320–9.\nCole M, McCusker J, Dendukuri N, Han L. The prognostic significance of subsyndromal delirium in elderly medical inpatients. J Am Geriatr Soc. 2003;51:754–60.\nMarcantonio E, Ta T, Duthie E, Resnick NM. Delirium severity and psychomotor types: their relationship with outcomes after hip fracture repair. J Am Geriatr Soc. 2002;50:850–7.\nCole MG, Ciampi A, Belzile E, Dubuc-Sarrasin M. Subsyndromal delirium in older people: a systematic review of frequency, risk factors, course and outcomes. Int J Geriatr Psychiatry. 2013;28:771–80.\nCole MG, McCusker J, Ciampi A, Belzile E. The 6- and 12-month outcomes of older medical inpatients who recover from subsyndromal delirium. J Am Geriatr Soc. 2008;56:2093–9.\nMartinez-Velilla N, Alonso-Bouzon C, Cambra-Contin K, Ibanez-Beroiz B, Alonso-Renedo J. Outcomes in complex patients with delirium and subsyndromal delirium one year after hospital discharge. Int Psychogeriatr. 2013;25:2087–8.\nShim J, DePalma G, Sands LP, Leung JM. Prognostic significance of postoperative subsyndromal delirium. Psychosomatics. 2015;56:644–51.\nBlazer DG, van Nieuwenhuizen AO. Evidence for the diagnostic criteria of delirium: an update. Curr Opin Psychiatry. 2012;25:239–43.\nLi HC, Chen YS, Chiu MJ, Fu MC, Huang GH, Chen CC. Delirium, subsyndromal delirium, and cognitive changes in individuals undergoing elective coronary artery bypass graft surgery. J Cardiovasc Nurs. 2015;30:340–5.\nMorrison RS, Magaziner J, Gilbert M, Koval KJ, McLaughlin MA, Orosz G, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003;58:76–81.\nCeriana P, Fanfulla F, Mazzacane F, Santoro C, Nava S. Delirium in patients admitted to a step-down unit: analysis of incidence and risk factors. J Crit Care. 2010;25:136–43.\nBenoit AG, Campbell BI, Tanner JR, Staley JD, Wallbridge HR, Biehl DR, et al. Risk factors and prevalence of perioperative cognitive dysfunction in abdominal aneurysm patients. J Vasc Surg. 2005;42:884–90.\nKosar CM, Tabloski PA, Travison TG, Jones RN, Schmitt EM, Puelle MR, et al. Effect of preoperative pain and depressive symptoms on the development of postoperative delirium. Lancet Psychiatry. 2014;1:431–6.\nMeagher D, O'Regan N, Ryan D, Connolly W, Boland E, O'Caoimhe R, et al. Frequency of delirium and subsyndromal delirium in an adult acute hospital population. Br J Psychiatry. 2014;205:478–85.\nTakeuchi D, Koide N, Suzuki A, Ishizone S, Shimizu F, Tsuchiya T, et al. Postoperative complications in elderly patients with gastric cancer. J Surg Res. 2015;198:317–26.\nShin YH, Kim DK, Jeong HJ. Impact of surgical approach on postoperative delirium in elderly patients undergoing gastrectomy: laparoscopic versus open approaches. Korean J Anesthesiol. 2015;68:379–85.\nLi QG, Li P, Tang D, Chen J, Wang DR. Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol. 2013;19:4060–5.\nYamada H, Kojima K, Inokuchi M, Kawano T, Sugihara K. Laparoscopy-assisted gastrectomy in patients older than 80. J Surg Res. 2010;161:259–63.\nOtani Y, Kubota T, Kumai K, Ohgami M, Hayashi N, Ishikawa Y, et al. Surgery for gastric carcinoma in patients more than 85 years of age. J Gastroenterol Hepatol. 2000;15:507–11.\nCole MG. Subsyndromal delirium in old age: conceptual and methodological issues. Int Psychogeriatr. 2013;25:863–6.\nTrzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the delirium rating scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatr Clin Neurosci. 2001;13:229–42.\nTrzepacz PT, Franco JG, Meagher DJ, Lee Y, Kim JL, Kishi Y, et al. Phenotype of subsyndromal delirium using pooled multicultural delirium rating scale--Revised-98 data. J Psychosom Res. 2012;73:10–7.\nBoettger S, Nunez DG, Meyer R, Richter A, Schubert M, Jenewein J. Subsyndromal delirium in the intensive care setting: phenomenological characteristics and discrimination of subsyndromal delirium versus no and full-syndromal delirium. Palliat Support Care. 2018;16:3–13.\nSepulveda E, Leonard M, Franco JG, Adamis D, McCarthy G, Dunne C, et al. Subsyndromal delirium compared with delirium, dementia, and subjects without delirium or dementia in elderly general hospital admissions and nursing home residents. Alzheimers Dement (Amst). 2017;7:1–10.\nFranco JG, Trzepacz PT, Meagher DJ, Kean J, Lee Y, Kim JL, et al. Three core domains of delirium validated using exploratory and confirmatory factor analyses. Psychosomatics. 2013;54:227–38.\nFranco JG, Trzepacz PT, Mejia MA, Ochoa SB. Factor analysis of the Colombian translation of the Delirium Rating Scale (DRS), Revised-98. Psychosomatics. 2009;50:255–62.\nLee Y, Ryu J, Lee J, Kim HJ, Shin IH, Kim JL, et al. Korean version of the delirium rating scale-revised-98: reliability and validity. Psychiatry Investig. 2011;8:30–8.\nKang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc. 1997;15:300–8.\nChoi SH, Park MH. Three screening methods for cognitive dysfunction using the Mini-Mental State Examination and Korean Dementia Screening Questionnaire. Geriatr Gerontol Int. 2016;16:252–8.\nFolstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.\nPark J, Kwon Y. Standardization study of the Korean version of the Mini-Mental State Examination (MMSE-K) for older adults -part II: cutoffs and diagnostic validity. J Korean Neuropsychiatr Assoc. 1989;28:508–13.\nZigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.\nSinger S, Kuhnt S, Gotze H, Hauss J, Hinz A, Liebmann A, et al. Hospital anxiety and depression scale cutoff scores for cancer patients in acute care. Br J Cancer. 2009;100:908–12.\nMollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep Med Rev. 2016;25:52–73.\nBuysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.\nCarpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh sleep quality index. J Psychosom Res. 1998;45:5–13.\nKhan BA, Zawahiri M, Campbell NL, Boustani MA. Biomarkers for delirium--a review. J Am Geriatr Soc. 2011;59(Suppl 2):S256–61.\nAndrosova G, Krause R, Winterer G, Schneider R. Biomarkers of postoperative delirium and cognitive dysfunction. Front Aging Neurosci. 2015;7:112.\nTrabold B, Metterlein T. Postoperative delirium: risk factors, prevention, and treatment. J Cardiothorac Vasc Anesth. 2014;28:1352–60.\nBond SM, Dietrich MS, Shuster JL Jr, Murphy BA. Delirium in patients with head and neck cancer in the outpatient treatment setting. Support Care Cancer. 2012;20:1023–30.\nBreu A, Stransky M, Metterlein T, Werner T, Trabold B. Subsyndromal delirium after cardiac surgery. Scand Cardiovasc J. 2015;49:207–12.\nOh YS, Kim DW, Chun HJ, Yi HJ. Incidence and risk factors of acute postoperative delirium in geriatric neurosurgical patients. J Korean Neurosurg Soc. 2008;43:143–8.\nInouye SK, Zhang Y, Jones RN, Kiely DK, Yang F, Marcantonio ER. Risk factors for delirium at discharge: development and validation of a predictive model. Arch Intern Med. 2007;167:1406–13.\nKim MC, Kim W, Kim HH, Ryu SW, Ryu SY, Song KY, et al. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale korean multicenter study. Ann Surg Oncol. 2008;15:2692–700.\nSeo HS, Lee HH. Short-term outcomes of three-port totally laparoscopic distal gastrectomy in the treatment of gastric cancer: comparison with a four-port approach using a propensity score matching analysis. J Laparoendosc Adv Surg Tech A. 2016;26:531–5.\nAlvarez-Perez FJ, Paiva F. Prevalence and risk factors for delirium in acute stroke patients. a retrospective 5-years clinical series. J Stroke Cerebrovasc Dis. 2016;\nZuliani G, Bonetti F, Magon S, Prandini S, Sioulis F, D'Amato M, et al. Subsyndromal delirium and its determinants in elderly patients hospitalized for acute medical illness. J Gerontol A Biol Sci Med Sci. 2013;68:1296–302.\nAlvarez-Perez FJ, Paiva F. Prevalence and risk factors for delirium in acute stroke patients. a retrospective 5-years clinical series. J Stroke Cerebrovasc Dis. 2017;26:567–73.\nRaats JW, van Eijsden WA, Crolla RM, Steyerberg EW, van der Laan L. Risk factors and outcomes for postoperative delirium after major surgery in elderly patients. PLoS One. 2015;10:e0136071.\nStern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11:1006–12.\nStern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271:1004–10.\nJones RN, Yang FM, Zhang Y, Kiely DK, Marcantonio ER, Inouye SK. Does educational attainment contribute to risk for delirium? A potential role for cognitive reserve. J Gerontol A Biol Sci Med Sci. 2006;61:1307–11.\nGrichnik KP, Ijsselmuiden AJ, D'Amico TA, Harpole DH Jr, White WD, Blumenthal JA, et al. Cognitive decline after major noncardiac operations: a preliminary prospective study. Ann Thorac Surg. 1999;68:1786–91.\nSuk H, Kwon OK, Yu W. Preoperative quality of life in patients with gastric cancer. J Gastric Cancer. 2015;15:121–6.\nSaczynski JS, Inouye SK, Kosar C, Tommet D, Marcantonio ER, Fong T, et al. Cognitive and brain reserve and the risk of postoperative delirium in older patients. Lancet Psychiatry. 2014;1:437–43.\nJankowski CJ, Trenerry MR, Cook DJ, Buenvenida SL, Stevens SR, Schroeder DR, et al. Cognitive and functional predictors and sequelae of postoperative delirium in elderly patients undergoing elective joint arthroplasty. Anesth Analg. 2011;112:1186–93.\nFritz BA, Kalarickal PL, Maybrier HR, Muench MR, Dearth D, Chen Y, et al. Intraoperative electroencephalogram suppression predicts postoperative delirium. Anesth Analg. 2016;122:234–42.\nTurner G, Clegg A. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing. 2014;43:744–7.\nJung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50:303–16.",{"EN":761},"Subsyndromal delirium, a condition in which patients exhibit some, but not all, of the symptoms of delirium, can negatively affect the outcomes of patients with cancer. However, the incidence of subsyndromal delirium in patients with gastric cancer is unknown. Here, we investigated the incidence and risk factors of subsyndromal delirium after curative resection of gastric cancer. We recruited consecutive patients with gastric cancer who were scheduled for curative resection at a tertiary hospital. Patients’ subsyndromal delirium symptoms were serially assessed preoperatively and 1, 2, 3, and 7 days postoperatively using the Delirium Rating Scale-Revised-98 (DRS-R-98). A DRS-R-98 score of 8–14 at any postoperative assessment was considered to indicate subsyndromal delirium. Sociodemographic and pre−\u002Fintra-operative clinical data were also assessed. Logistic regression analyses were used to determine the associated risk factors. Data were analysed from 163 out of 217 eligible patients. Postoperative delirium occurred in one patient (0.6%) and subsyndromal delirium occurred in 19 patients (11.7%). Age ≥ 70 years (odds ratio, [OR] 3.85; 95% confidence interval [CI], 1.36–10.92; p = 0.011) and education level ≤ 9 years (OR, 3.98; 95% CI, 1.39–11.41; p = 0.010) were independent risk factors of subsyndromal delirium after adjusting for preoperative cognitive function. Other pre−\u002Fintra-operative variables including anxiety\u002Fdepression, poor sleep quality, and anaesthesia duration were not associated with subsyndromal delirium. In contrast to the low incidence of delirium among patients undergoing curative resection of gastric cancer, a substantial proportion of such patients experienced subsyndromal delirium. Considering the prognostic implications, more careful detection and management of subsyndromal delirium may be warranted in patients with gastric cancer.",{"EN":763},"Incidence and risk factors of subsyndromal delirium after curative resection of gastric cancer",{"VOID":765},"10.1186\u002Fs12885-018-4681-2","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-018-4681-2",[768,793,818,835,847,866,885,901,916,928,943],{"id":769,"sortIndex":115,"researcher":20,"roles":770,"affiliations":771,"properties":790},"f22a6b4c-ce15-40e9-a183-4085e287848d",[186],[772,782],{"id":773,"sortIndex":115,"affiliation":774,"properties":781},"2752cd79-61c3-442d-bc6b-1e4b27fc9397",{"id":775,"createTime":776,"updateTime":776,"relativeEntities":777,"slug":20,"properties":778,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"817fcb2c-3754-4d45-8902-f09654803ca8","2023-12-19T07:41:39.290+00:00",[],{"title":779},{"VI":780},"Department of Psychiatry, Gyeonggi Provincial Medical Center Uijeongbu Hospital, Uijeongbu, Korea",{},{"id":20,"sortIndex":21,"affiliation":783,"properties":20},{"id":784,"createTime":785,"updateTime":785,"relativeEntities":786,"slug":20,"properties":787,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"8b7cb033-6118-4ab1-bcb7-fd38391fd3aa","2023-12-19T07:41:39.269+00:00",[],{"title":788},{"VI":789},"Public Health and Medical Service, Seoul National University Hospital, Seoul, Korea",{"title":791},{"VI":792},"Kwang-Min Lee",{"id":794,"sortIndex":68,"researcher":20,"roles":795,"affiliations":796,"properties":815},"984e25a4-c734-43a1-b586-2f5283818307",[186],[797,805],{"id":20,"sortIndex":21,"affiliation":798,"properties":20},{"id":799,"createTime":800,"updateTime":800,"relativeEntities":801,"slug":20,"properties":802,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"3b82c460-2c75-427c-b327-181ea3b7537d","2023-12-19T07:41:39.348+00:00",[],{"title":803},{"VI":804},"Department of Psychiatry, Seoul National University Hospital, Seoul, Korea",{"id":806,"sortIndex":115,"affiliation":807,"properties":814},"971755c0-8c4f-4f84-bdd6-3bd3c963efee",{"id":808,"createTime":809,"updateTime":809,"relativeEntities":810,"slug":20,"properties":811,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"917e46cc-7d0b-4b83-9808-58647de7d695","2023-12-19T07:42:09.083+00:00",[],{"title":812},{"VI":813},"Department of Psychiatry and Behavioral Sciences, Seoul National University College of Medicine, Seoul, Korea",{},{"title":816},{"VI":817},"Bong-Jin Hahm",{"id":819,"sortIndex":156,"researcher":20,"roles":820,"affiliations":821,"properties":832},"19846344-1c13-460b-9129-29b215665ae8",[186],[822],{"id":20,"sortIndex":21,"affiliation":823,"properties":20},{"id":824,"createTime":825,"updateTime":826,"relativeEntities":827,"slug":828,"properties":829,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"4b67494e-4706-4e81-84a6-95041cc83f99","2024-01-09T14:35:57.093+00:00","2024-09-26T03:08:16.286+00:00",[],"Department-of-Surgery-Seoul-National-University-Hospital-Seoul-Korea",{"title":830},{"VI":831},"Department of Surgery, Seoul National University Hospital, Seoul, Korea",{"title":833},{"VI":834},"Yun-Suhk Suh",{"id":836,"sortIndex":649,"researcher":20,"roles":837,"affiliations":838,"properties":844},"770e3f73-6ce5-41ae-9d79-9f41204cd302",[186],[839],{"id":20,"sortIndex":21,"affiliation":840,"properties":20},{"id":824,"createTime":825,"updateTime":826,"relativeEntities":841,"slug":828,"properties":842,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":843},{"VI":831},{"title":845},{"VI":846},"Hyuk-Joon Lee",{"id":848,"sortIndex":21,"researcher":20,"roles":849,"affiliations":850,"properties":863},"74c91b68-541e-468c-84c3-a6171d80ea7c",[186],[851,856],{"id":20,"sortIndex":21,"affiliation":852,"properties":20},{"id":799,"createTime":800,"updateTime":800,"relativeEntities":853,"slug":20,"properties":854,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":855},{"VI":804},{"id":857,"sortIndex":115,"affiliation":858,"properties":862},"fbc8c84c-b1dc-428a-ad03-dd7344d6299d",{"id":808,"createTime":809,"updateTime":809,"relativeEntities":859,"slug":20,"properties":860,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":861},{"VI":813},{},{"title":864},{"VI":865},"Heesung Hwang",{"id":867,"sortIndex":211,"researcher":20,"roles":868,"affiliations":869,"properties":882},"678a10e7-5144-4f02-ba4f-74017fbc46b0",[186],[870,875],{"id":20,"sortIndex":21,"affiliation":871,"properties":20},{"id":799,"createTime":800,"updateTime":800,"relativeEntities":872,"slug":20,"properties":873,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":874},{"VI":804},{"id":876,"sortIndex":115,"affiliation":877,"properties":881},"c083c7ca-4a86-4bc3-b89b-4b00a3e34984",{"id":808,"createTime":809,"updateTime":809,"relativeEntities":878,"slug":20,"properties":879,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":880},{"VI":813},{},{"title":883},{"VI":884},"Kyung-Lak Son",{"id":886,"sortIndex":224,"researcher":20,"roles":887,"affiliations":888,"properties":898},"2910bdc1-6760-46d9-b98c-c951b3e6635c",[186],[889],{"id":20,"sortIndex":21,"affiliation":890,"properties":20},{"id":891,"createTime":892,"updateTime":892,"relativeEntities":893,"slug":894,"properties":895,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"da4772e5-320f-4719-8f32-69e23c37e64a","2024-04-14T10:47:15.930+00:00",[],"Department-of-Human-Factors-Engineering-Ulsan-National-Institute-of-Science-and-Technology-Ulsan-Korea",{"title":896},{"EN":897},"Department of Human Factors Engineering, Ulsan National Institute of Science and Technology, Ulsan, Korea",{"title":899},{"VI":900},"Dooyoung Jung",{"id":902,"sortIndex":184,"researcher":20,"roles":903,"affiliations":904,"properties":913},"f30a2def-e443-4644-a27a-80138c456973",[186],[905],{"id":20,"sortIndex":21,"affiliation":906,"properties":20},{"id":907,"createTime":908,"updateTime":908,"relativeEntities":909,"slug":20,"properties":910,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"1147ad96-8608-4c5c-acb3-4eee52a474ba","2023-12-19T07:41:39.375+00:00",[],{"title":911},{"VI":912},"Department of Psychiatry, Inha University Hospital, Incheon, Korea",{"title":914},{"VI":915},"Won-Hyoung Kim",{"id":917,"sortIndex":57,"researcher":20,"roles":918,"affiliations":919,"properties":925},"19fbc339-daef-472e-a3f2-de72c75357d9",[186],[920],{"id":20,"sortIndex":21,"affiliation":921,"properties":20},{"id":824,"createTime":825,"updateTime":826,"relativeEntities":922,"slug":828,"properties":923,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":924},{"VI":831},{"title":926},{"VI":927},"Han-Kwang Yang",{"id":929,"sortIndex":373,"researcher":20,"roles":930,"affiliations":931,"properties":940},"c2c24af3-e051-4740-a93b-5fd060c8b13d",[186],[932],{"id":20,"sortIndex":21,"affiliation":933,"properties":20},{"id":934,"createTime":935,"updateTime":935,"relativeEntities":936,"slug":20,"properties":937,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"70daced2-29eb-4673-b02f-b66bff30b3ba","2023-12-19T07:42:09.110+00:00",[],{"title":938},{"VI":939},"Department of Health Management, Armed Forces Medical Command, Seongnam, Korea",{"title":941},{"VI":942},"Joo-Young Lee",{"id":944,"sortIndex":114,"researcher":20,"roles":945,"affiliations":946,"properties":952},"95b96f0f-d26a-4190-88d3-3065ccd43246",[186],[947],{"id":20,"sortIndex":21,"affiliation":948,"properties":20},{"id":824,"createTime":825,"updateTime":826,"relativeEntities":949,"slug":828,"properties":950,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":951},{"VI":831},{"title":953},{"VI":954},"Seong-Ho Kong",{"url":766,"publisher":956,"properties":984},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":957,"slug":10,"properties":958,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":962,"manageAffiliations":963,"indexDatabases":964,"url":20,"thumbnailPath":20,"statistic":979,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":959,"title":960,"url":961},{"VOID":13},{"EN":15},{"VOID":17},[],[],[965,972],{"id":72,"indexDatabase":966,"url":87,"indexYears":20,"academicFieldIds":971,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":967,"label":968,"description":969,"key":83,"publicationTags":970,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":973,"url":104,"indexYears":105,"academicFieldIds":978,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":974,"label":975,"description":976,"key":101,"publicationTags":977,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":980,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":981,"totalCitation":142,"totalCitationByYear":982,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":983,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":985,"pages":986},{"VOID":294},{"VOID":987},"1-10","2018-07-27",{"id":990,"createTime":991,"updateTime":992,"relativeEntities":993,"slug":994,"properties":995,"entityType":177,"verifyStatus":178,"verifyTime":1004,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1005,"fullTextUrl":20,"authors":1006,"publicationType":262,"publisherRelationship":1170,"citationCount":20,"citationInfo":20,"publishDate":1203,"publishYear":1204,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"3ed79de5-ec83-43d1-a214-09d62e322945","2024-02-07T12:56:10.111+00:00","2025-01-25T23:59:27.153+00:00",[],"Phase-II-trial-of-selective-internal-radiation-therapy-and-systemic-chemotherapy-for-liver-predominant-metastases-from-pancreatic-adenocarcinoma",{"references":996,"abstract":998,"title":1000,"doi":1002},{"VOID":997},"Pancreatic Action Support Network: the alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide. http:\u002F\u002Fwww.pancan.org\u002Fsection_research\u002Freports\u002Fpdf\u002Fincidence_report_2012.pdf.\nWorld health Organization. Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. GLOBOCAN (International Agency for Research on Cancer). 2008. http:\u002F\u002Fglobocan.iarc.fr\u002F.\nJemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.\nBurris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer. J Clin Oncol. 1997;15:2403–13.\nConroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.\nLorgis V, Chauffert B, Gentil J, Ghiringhelli F. Influence of localization of primary tumor on effectiveness of 5-Fluorouracil\u002Fleucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res. 2012;32:4125–30.\nHosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.\nPeddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13:497–501.\nEvans DB, Abbruzzese JL Willett CG. Cancer of the pancreas. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1126–61.\nSangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868–78.\nSalem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.\nSangro B, Iñarrairaegui M, Bilbao JI. Radioembolisation for hepatocellular carcinoma. J Hepatol. 2012;56:464–73.\nKennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.\nKing J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9.\nHendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687–94.\nVan Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil\u002Fleucovorin chemotherapy versus fluorouracil\u002Fleucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.\nKosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol. 2011;22:780–6.\nSharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099–106.\nColdwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:800–4.\nJakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683–90.\nBangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621–8.\nCao C, Yan TD, Morris DL, Bester L. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori. 2010;96:955–8.\nGulec SA, Wheeler J, Pennington K, Hall M, Bruetman D, Westbrook C, et al. Chemotherapy with Yttrium-90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer. J Interven Oncol. 2009;2:84–92.\nKornek GV, Pötter R, Selzer E, Schratter A, Ulrich-Pur H, Rogy M, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys. 2001;49:665–71.\nde Lange SM, van Groeningen CJ, Meijer OW, Cuesta MA, Langendijk JA, van Riel JM, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer. 2002;38:1212–7.\nLouvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.\nColucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–51.\nHerrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–7.\nCunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8.\nPhilip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.\nKindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617–22.\nMoore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.\nSangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538–46.\nWhiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. MJA. 2002;177:432–5.\nJakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187–95.\nGray BN, Burton MA, Kelleher DK, Anderson J, Klemp P. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol. 1989;42:192–6.\nNace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261.\nvan Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27:4089–95.",{"EN":999},"This prospective, open-label phase II study assessed the impact of liver-directed therapy with selective internal radiation therapy (SIRT) and systemic chemotherapy on progression-free survival (PFS) in liver-dominant metastatic pancreatic adenocarcinoma. Patients received yttrium-90-labelled (90Y) resin microspheres (SIR-Spheres; Sirtex Medical Limited, Sydney, Australia) as a single procedure on day 2 of the first weekly cycle of 5-fluorouracil (5FU; 600 mg\u002Fm2) with the option to switch to gemcitabine (1000 mg\u002Fm2) after 8 weeks of 5FU. Statistical analysis was conducted using Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA). The primary endpoint of the study was PFS in the liver, with a median of ≥16 weeks defined as the threshold for clinical significance. PFS and overall survival (OS) were summarised by the Kaplan-Meier method using non-parametric estimates of the survivor function. Fourteen eligible patients were enrolled; ten had primary tumour in situ and eight had liver-only metastases. Patients received a median 90Y activity of 1.1 GBq and 8 weekly doses of 5FU; seven patients received a median of two doses of gemcitabine. Disease control in the liver was 93 % (two confirmed partial responses [PR], one unconfirmed PR, ten stable disease). Median reduction in cancer antigen 19–9 was 72 %. Median PFS was 5.2 months in the liver, which met the primary endpoint of the study, and 4.4 months at any site. PFS was prolonged in those with a resected primary compared with patients with primary in situ (median 7.8 vs. 3.4 months; p = 0.017). Median OS was 5.5 months overall and 13.6 months in patients with a resected primary. Grade 3\u002F4 adverse events occurred in eight (57 %) patients during days 0–60. There was one sudden death and another patient who died from possible treatment-related liver failure 7.0 months after SIRT. SIRT and chemotherapy appears to be an effective treatment for liver metastases from pancreatic cancer, likely to be of most benefit in selected patients with a resected primary tumour and liver only disease. Significant toxicity was observed and the safety of this approach in patients with metastatic pancreatic cancer will need to be confirmed in subsequent studies. Further study is warranted with SIRT and modern chemotherapies. \n                  \n                    ACTRN12606000015549\n                    \n                  \n                ",{"EN":1001},"Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma",{"VOID":1003},"10.1186\u002Fs12885-015-1822-8","2025-01-25T23:59:27.152+00:00","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-015-1822-8",[1007,1024,1039,1054,1081,1093,1108,1120,1135,1154],{"id":1008,"sortIndex":156,"researcher":20,"roles":1009,"affiliations":1010,"properties":1021},"d0078187-9d0e-4768-964d-312ce3b84415",[186],[1011],{"id":20,"sortIndex":21,"affiliation":1012,"properties":20},{"id":1013,"createTime":1014,"updateTime":1015,"relativeEntities":1016,"slug":1017,"properties":1018,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"4db6e4ed-c90a-4d2e-acca-0ddb5622ad2f","2024-01-11T07:01:08.198+00:00","2024-12-30T07:04:50.625+00:00",[],"Department-of-Radiology-Royal-Melbourne-Hospital-Melbourne-Australia",{"title":1019},{"VI":1020},"Department of Radiology, Royal Melbourne Hospital, Melbourne, Australia",{"title":1022},{"VI":1023},"Richard Dowling",{"id":1025,"sortIndex":57,"researcher":20,"roles":1026,"affiliations":1027,"properties":1036},"9b8b2edf-7d39-42a9-b04a-bbbf8d0f55e9",[186],[1028],{"id":20,"sortIndex":21,"affiliation":1029,"properties":20},{"id":1030,"createTime":1031,"updateTime":1031,"relativeEntities":1032,"slug":20,"properties":1033,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"7504a66f-c56e-4849-b4b6-934d94311914","2024-02-07T12:56:11.072+00:00",[],{"title":1034},{"VI":1035},"Perth Oncology, Mount Hospital, Perth, Australia",{"title":1037},{"VI":1038},"Guy A. van Hazel",{"id":1040,"sortIndex":224,"researcher":20,"roles":1041,"affiliations":1042,"properties":1051},"323b1985-8f93-4185-8ed8-3110b6623201",[186],[1043],{"id":20,"sortIndex":21,"affiliation":1044,"properties":20},{"id":1045,"createTime":1046,"updateTime":1046,"relativeEntities":1047,"slug":20,"properties":1048,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"80384ff4-af87-4465-a83d-9dcd4ba28ee9","2024-02-07T12:56:10.528+00:00",[],{"title":1049},{"VI":1050},"Sirtex Medical Limited, Sydney, Australia",{"title":1052},{"VI":1053},"David N. Cade",{"id":1055,"sortIndex":211,"researcher":20,"roles":1056,"affiliations":1057,"properties":1078},"9b5c6fea-f743-41d8-9565-8ebe6ca82e24",[186],[1058,1068],{"id":20,"sortIndex":21,"affiliation":1059,"properties":20},{"id":1060,"createTime":1061,"updateTime":1062,"relativeEntities":1063,"slug":1064,"properties":1065,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"00776262-654b-429b-a58f-c2e98a14585e","2024-02-07T12:56:10.200+00:00","2025-06-11T13:57:54.881+00:00",[],"Department-of-Medical-Oncology-Royal-Melbourne-Hospital-Parkville-Australia",{"title":1066},{"VI":1067},"Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Australia",{"id":1069,"sortIndex":115,"affiliation":1070,"properties":1077},"b0bfffb2-fa64-4d25-9f98-c594c865dc75",{"id":1071,"createTime":1072,"updateTime":1072,"relativeEntities":1073,"slug":20,"properties":1074,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"7cc20d68-44f3-48aa-ac0c-28958fe67371","2024-02-07T12:56:10.460+00:00",[],{"title":1075},{"VI":1076},"Department of Medical Oncology, Western Hospital, Melbourne, Australia",{},{"title":1079},{"VI":1080},"Lara Lipton",{"id":1082,"sortIndex":184,"researcher":20,"roles":1083,"affiliations":1084,"properties":1090},"9156aa93-a131-4c92-8b92-f0d123f6e5b2",[186],[1085],{"id":20,"sortIndex":21,"affiliation":1086,"properties":20},{"id":1045,"createTime":1046,"updateTime":1046,"relativeEntities":1087,"slug":20,"properties":1088,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1089},{"VI":1050},{"title":1091},{"VI":1092},"Michael J. Tapner",{"id":1094,"sortIndex":373,"researcher":20,"roles":1095,"affiliations":1096,"properties":1105},"6af4a256-c225-4c1a-8f2d-7ab15db3820b",[186],[1097],{"id":20,"sortIndex":21,"affiliation":1098,"properties":20},{"id":1099,"createTime":1100,"updateTime":1100,"relativeEntities":1101,"slug":20,"properties":1102,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"54ce1120-e722-4337-a01e-7450cd5ce83c","2024-02-07T12:56:10.683+00:00",[],{"title":1103},{"VI":1104},"Perth Radiological Clinic, Mount Hospital, Perth, Australia",{"title":1106},{"VI":1107},"David Price",{"id":1109,"sortIndex":115,"researcher":20,"roles":1110,"affiliations":1111,"properties":1117},"9ca39c9e-abe7-4eab-8865-998afe6327d4",[186],[1112],{"id":20,"sortIndex":21,"affiliation":1113,"properties":20},{"id":1071,"createTime":1072,"updateTime":1072,"relativeEntities":1114,"slug":20,"properties":1115,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1116},{"VI":1076},{"title":1118},{"VI":1119},"Cuong Do",{"id":1121,"sortIndex":114,"researcher":20,"roles":1122,"affiliations":1123,"properties":1132},"82c1f43d-9ba9-43cb-a546-94f978afe7b3",[186],[1124],{"id":20,"sortIndex":21,"affiliation":1125,"properties":20},{"id":1126,"createTime":1127,"updateTime":1127,"relativeEntities":1128,"slug":20,"properties":1129,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"c40c0d11-3f8d-46b2-9ff0-84ae32ed869b","2024-02-07T12:56:10.716+00:00",[],{"title":1130},{"VI":1131},"Mount Nuclear Medicine, Mount Hospital, Perth, Australia",{"title":1133},{"VI":1134},"Geoff D. Bower",{"id":1136,"sortIndex":21,"researcher":20,"roles":1137,"affiliations":1138,"properties":1151},"e3d44440-afc1-4402-a25c-9fa385ffa876",[186],[1139,1146],{"id":1140,"sortIndex":115,"affiliation":1141,"properties":1145},"c55f4d0b-1d0c-4a85-bec7-639a756b44c0",{"id":1071,"createTime":1072,"updateTime":1072,"relativeEntities":1142,"slug":20,"properties":1143,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1144},{"VI":1076},{},{"id":20,"sortIndex":21,"affiliation":1147,"properties":20},{"id":1060,"createTime":1061,"updateTime":1062,"relativeEntities":1148,"slug":1064,"properties":1149,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1150},{"VI":1067},{"title":1152},{"VI":1153},"Peter Gibbs",{"id":1155,"sortIndex":649,"researcher":20,"roles":1156,"affiliations":1157,"properties":1167},"500d27a4-b2c4-4bc6-a826-62698f82eaa4",[186],[1158],{"id":20,"sortIndex":21,"affiliation":1159,"properties":20},{"id":1160,"createTime":1161,"updateTime":1161,"relativeEntities":1162,"slug":1163,"properties":1164,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"f26756b2-36ba-4f1f-9004-b0b767a691f9","2024-04-06T16:47:59.194+00:00",[],"Department-of-Nuclear-Medicine-Royal-Melbourne-Hospital-Melbourne-Australia",{"title":1165},{"VI":1166},"Department of Nuclear Medicine, Royal Melbourne Hospital, Melbourne, Australia",{"title":1168},{"VI":1169},"Meir Lichtenstein",{"url":1005,"publisher":1171,"properties":1199},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1172,"slug":10,"properties":1173,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1177,"manageAffiliations":1178,"indexDatabases":1179,"url":20,"thumbnailPath":20,"statistic":1194,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":1174,"title":1175,"url":1176},{"VOID":13},{"EN":15},{"VOID":17},[],[],[1180,1187],{"id":72,"indexDatabase":1181,"url":87,"indexYears":20,"academicFieldIds":1186,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":1182,"label":1183,"description":1184,"key":83,"publicationTags":1185,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":1188,"url":104,"indexYears":105,"academicFieldIds":1193,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":1189,"label":1190,"description":1191,"key":101,"publicationTags":1192,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":1195,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":1196,"totalCitation":142,"totalCitationByYear":1197,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":1198,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":1200,"pages":1202},{"VOID":1201},"15",{"VOID":454},"2015-10-26",2015,{"id":1206,"createTime":1207,"updateTime":1208,"relativeEntities":1209,"slug":1210,"properties":1211,"entityType":177,"verifyStatus":178,"verifyTime":1208,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1220,"fullTextUrl":20,"authors":1221,"publicationType":262,"publisherRelationship":1329,"citationCount":20,"citationInfo":20,"publishDate":1363,"publishYear":1364,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"227e9b37-c3ad-4bc1-8b4f-01077b4378ab","2023-12-19T11:42:29.309+00:00","2024-12-18T23:59:16.972+00:00",[],"Intraepithelial-lymphocytes-are-indicators-of-better-prognosis-in-surgically-resected-endometrioid-type-endometrial-carcinomas-at-early-and-advanced-stages",{"references":1212,"abstract":1214,"title":1216,"doi":1218},{"VOID":1213},"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.\nLortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354–61.\nJapan Society of Obstetrics and Gynecology. Patient annual report for 2017. Acta Obstet Gynaecol Jpn. 2019;71(5):669–724.\nThe editorial board of the cancer statistics in Japan. Cancer Statistics in Japan 2018. Tokyo: The Foundation for Promotion of Cancer Research; 2019. p. 62.\nGuo F, Dong Y, Tan Q, Kong J, Yu B. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis Markers. 2020;2020:1805764.\nKondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10(13):4450–6.\nde Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10.\nČermáková P, Melichar B, Tomšová M, Zoul Z, Kalábová H, Spaček J, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res. 2014;34(10):5555–61.\nIno K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res. 2008;14(8):2310–7.\nSuemori T, Susumu N, Iwata T, Banno K, Yamagami W, Hirasawa A, et al. Intratumoral CD8+ lymphocyte infiltration as a prognostic factor and its relationship with cyclooxygenase 2 expression and microsatellite instability in endometrial cancer. Int J Gynecol Cancer. 2015;25(7):1165–72.\nGalon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumors. J Pathol. 2014;232(2):199–209.\nPagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.\nMills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32(6):463–88.\nAllavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9.\nSoeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, et al. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol. 2008;109(1):122–8.\nTakanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57(2):138–42.\nForssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13(5):1472–9.\nAmbros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer. 1992;69(6):1424–31.\nYamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget. 2018;9(5):5652–64.\nMiyai K, Mikoshi A, Hamabe F, Nakanishi K, Ito K, Tsuda H, et al. Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. Mod Pathol. 2019;32(10):1536–43.\nHendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311–35.\nKübler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol. 2014;135(2):176–83.\nEspinosa I, José Carnicer M, Catasus L, Canet B, D'Angelo E, Zannoni GF, et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol. 2010;34(11):1708–14.\nZheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A, et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(29):48436–52.\nFerguson SE, Aronson M, Pollett A, Eiriksson LR, Oza AM, Gallinger S, et al. Performance characteristics of screening strategies for lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer. 2014;120(24):3932–9.\nShia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39(1):116–25.\nTalhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25(8):2537–48.\nNelson GS, Pink A, Lee S, Han G, Morris D, Ogilvie T, et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol. 2013;131(2):309–14.\nDiaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013;88(1):154–67.\nRuiz I, Martín-Arruti M, Lopez-Lopez E, Garcia-Orad A. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type. Gynecol Oncol. 2014;134(1):20–3.\nNoma T, Makino T, Ohshima K, Sugimura K, Miyata H, Honma K, et al. Immunoscore signatures in surgical specimens and tumor-infiltrating lymphocytes in pretreatment biopsy predict treatment efficacy and survival in esophageal cancer. Ann Surg. 2021. https:\u002F\u002Fdoi.org\u002F10.1097\u002FSLA.0000000000005104.\nHuang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8.",{"EN":1215},"Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) may be useful prognostic indicators in endometrial cancer. However, standardized assessment methods and the prognostic roles of these cells in different stage groups are unclear. Formalin-fixed paraffin-embedded tissue samples of 107 endometrioid-type endometrial carcinomas (EECs) comprising 60 stage IB and 47 stage IIIC or IVB cases were evaluated. CD3+ TILs, CD8+ TILs, CD68+ TAMs, and CD163+ TAMs were detected by immunohistochemistry, and their densities were evaluated by semiquantitative and quantitative methods. TILs within tumor epithelial cell nests (E-TILs) and those within the stroma at the invasive front (S-TILs) were evaluated separately for CD3+ and CD8+ cells. The “TIL score” was defined as the sum of semiquantitative scores of CD3+ E-TILs, CD3+ S-TILs, CD8+ E-TILs, and CD8+ S-TILs. For TAMs, the area of CD68+ and CD163+ cells in the invasive margin were semiquantitatively and quantitatively evaluated. Clinicopathological and prognostic implications of TILs and TAMs in stage IB and IIIC\u002FIVB EECs were examined by Cox univariate and multivariate analyses. By Cox univariate analyses, semiquantitatively low CD3+ E-TILs, low CD8+ E-TILs, and low “TIL score” were significantly correlated with worse prognosis in stage IB patients (P = 0.011, 0.040, and 0.039, respectively). Likewise, low CD3+ E-TILs and low CD8+ E-TILs, by both semiquantitative (P = 0.011 and 0.0051) and quantitative evaluations (P \u003C 0.0001, and P = 0.0015) and low “TIL score” (P = 0.020) were significantly correlated with worse prognosis in stage IIIC\u002FIVB patients. By Cox multivariate analyses, semiquantitatively low CD3+ E-TILs and low CD8+ E-TILs, low “TIL score”, and quantitatively low CD3+ E-TILs and low CD8+ E-TILs were independent worse prognostic factors in stage IIIC\u002FIVB (P = 0.0011, 0.0053, 0.012, \u003C 0.0001, and \u003C 0.0001, respectively). CD68+ or CD163+ TAMs were not correlated with prognosis in any patients. Both semiquantitatively and quantitatively low E-TILs, are correlated with worse prognosis in both early and advanced stage patients with EECs. In particular, CD3+ E-TILs and CD8+ E-TILs are potentially useful prognostic markers in patients with EEC regardless of the stage.",{"EN":1217},"Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages",{"VOID":1219},"10.1186\u002Fs12885-022-09363-0","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-022-09363-0",[1222,1239,1254,1266,1278,1290,1302,1317],{"id":1223,"sortIndex":21,"researcher":20,"roles":1224,"affiliations":1225,"properties":1236},"6803ddea-bca9-4703-aab0-f026e738938f",[186],[1226],{"id":20,"sortIndex":21,"affiliation":1227,"properties":20},{"id":1228,"createTime":1229,"updateTime":1230,"relativeEntities":1231,"slug":1232,"properties":1233,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"beef5b52-e012-4e26-859c-6b93121e9fce","2024-01-12T00:09:51.813+00:00","2024-10-04T22:05:22.566+00:00",[],"Department-of-Basic-Pathology-National-Defense-Medical-College-Saitama-Japan",{"title":1234},{"VI":1235},"Department of Basic Pathology, National Defense Medical College, Saitama, Japan",{"title":1237},{"VI":1238},"Takako Kono-Sato",{"id":1240,"sortIndex":373,"researcher":20,"roles":1241,"affiliations":1242,"properties":1251},"47f6a487-1c9e-4d5c-a73d-05a52eb11f04",[186],[1243],{"id":20,"sortIndex":21,"affiliation":1244,"properties":20},{"id":1245,"createTime":1246,"updateTime":1246,"relativeEntities":1247,"slug":20,"properties":1248,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"7e034d54-f77e-4c7c-a0b5-f2789c5a9341","2023-12-19T11:42:29.349+00:00",[],{"title":1249},{"VI":1250},"Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa, Japan",{"title":1252},{"VI":1253},"Susumu Matsukuma",{"id":1255,"sortIndex":114,"researcher":20,"roles":1256,"affiliations":1257,"properties":1263},"fbf4b1fd-8bcd-4420-ac66-1927a86d87f1",[186],[1258],{"id":20,"sortIndex":21,"affiliation":1259,"properties":20},{"id":1228,"createTime":1229,"updateTime":1230,"relativeEntities":1260,"slug":1232,"properties":1261,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1262},{"VI":1235},{"title":1264},{"VI":1265},"Kimiya Sato",{"id":1267,"sortIndex":211,"researcher":20,"roles":1268,"affiliations":1269,"properties":1275},"f445c35f-17f3-4366-a75c-d589826dbdda",[186],[1270],{"id":20,"sortIndex":21,"affiliation":1271,"properties":20},{"id":1228,"createTime":1229,"updateTime":1230,"relativeEntities":1272,"slug":1232,"properties":1273,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1274},{"VI":1235},{"title":1276},{"VI":1277},"Yoji Yamagishi",{"id":1279,"sortIndex":115,"researcher":20,"roles":1280,"affiliations":1281,"properties":1287},"d8a72073-e851-4bd0-9383-3eee7d4f8550",[186],[1282],{"id":20,"sortIndex":21,"affiliation":1283,"properties":20},{"id":1245,"createTime":1246,"updateTime":1246,"relativeEntities":1284,"slug":20,"properties":1285,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1286},{"VI":1250},{"title":1288},{"VI":1289},"Kosuke Miyai",{"id":1291,"sortIndex":156,"researcher":20,"roles":1292,"affiliations":1293,"properties":1299},"3b072597-7894-468b-8e32-aa672fde762f",[186],[1294],{"id":20,"sortIndex":21,"affiliation":1295,"properties":20},{"id":1228,"createTime":1229,"updateTime":1230,"relativeEntities":1296,"slug":1232,"properties":1297,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1298},{"VI":1235},{"title":1300},{"VI":1301},"Hitoshi Tsuda",{"id":1303,"sortIndex":224,"researcher":20,"roles":1304,"affiliations":1305,"properties":1314},"8561e8d5-19cb-4327-a68f-ac2ce8400852",[186],[1306],{"id":20,"sortIndex":21,"affiliation":1307,"properties":20},{"id":1308,"createTime":1309,"updateTime":1309,"relativeEntities":1310,"slug":20,"properties":1311,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ac5789b4-cc14-4272-a47d-e9f3f9d2b07d","2023-12-11T16:28:19.568+00:00",[],{"title":1312},{"VI":1313},"Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan",{"title":1315},{"VI":1316},"Morikazu Miyamoto",{"id":1318,"sortIndex":184,"researcher":20,"roles":1319,"affiliations":1320,"properties":1326},"d7e58090-d2cd-4ed5-a850-b91f330fed5a",[186],[1321],{"id":20,"sortIndex":21,"affiliation":1322,"properties":20},{"id":1308,"createTime":1309,"updateTime":1309,"relativeEntities":1323,"slug":20,"properties":1324,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1325},{"VI":1313},{"title":1327},{"VI":1328},"Masashi Takano",{"url":1220,"publisher":1330,"properties":1358},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1331,"slug":10,"properties":1332,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1336,"manageAffiliations":1337,"indexDatabases":1338,"url":20,"thumbnailPath":20,"statistic":1353,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":1333,"title":1334,"url":1335},{"VOID":13},{"EN":15},{"VOID":17},[],[],[1339,1346],{"id":72,"indexDatabase":1340,"url":87,"indexYears":20,"academicFieldIds":1345,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":1341,"label":1342,"description":1343,"key":83,"publicationTags":1344,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":1347,"url":104,"indexYears":105,"academicFieldIds":1352,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":1348,"label":1349,"description":1350,"key":101,"publicationTags":1351,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":1354,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":1355,"totalCitation":142,"totalCitationByYear":1356,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":1357,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":1359,"pages":1361},{"VOID":1360},"22",{"VOID":1362},"1-15","2022-04-02",2022,{"id":1366,"createTime":1367,"updateTime":1368,"relativeEntities":1369,"slug":1370,"properties":1371,"entityType":177,"verifyStatus":178,"verifyTime":1368,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1380,"fullTextUrl":20,"authors":1381,"publicationType":262,"publisherRelationship":1448,"citationCount":20,"citationInfo":20,"publishDate":1481,"publishYear":1364,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"04c5410f-6b04-43fb-b2dc-1ff8d4e8a8e1","2023-11-25T08:22:52.826+00:00","2025-02-22T23:59:04.595+00:00",[],"Concomitant-Temozolomide-plus-radiotherapy-for-high-grade-and-recurrent-meningioma-a-retrospective-chart-review",{"references":1372,"abstract":1374,"title":1376,"doi":1378},{"VOID":1373},"Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurol. 2004;62:1210–2. https:\u002F\u002Fdoi.org\u002F10.1212\u002F01.Wnl.0000118300.82017.F4.\nDasanu CA, Samara Y, Codreanu I, et al. Systemic therapy for relapsed\u002Frefractory meningioma: is there potential for antiangiogenic agents? J Oncol Pharm Pract. 2019;25:638–47. https:\u002F\u002Fdoi.org\u002F10.1177\u002F1078155218799850.\nLe Rhun E, Taillibert S, Chamberlain MC. Systemic therapy for recurrent meningioma. Expert Rev Neurother. 2016;16:889–901. https:\u002F\u002Fdoi.org\u002F10.1080\u002F14737175.2016.1184087.\nScorsetti M, Alongi F, Clerici E, et al. Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. Tumori J. 2012;98:e67–71. https:\u002F\u002Fdoi.org\u002F10.1177\u002F030089161209800321.\nZhu H, Bi WL, Aizer A, et al. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Med. 2019;8:13–20. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcam4.1531.\nBi WL, Dunn IF. Current and emerging principles in surgery for meningioma. Chin Clin Oncol. 2017;6:S7. https:\u002F\u002Fdoi.org\u002F10.21037\u002Fcco.2017.06.10.\nGoldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS1470-2045(16)30321-7.\nCui C, Zhou L, Lian B, et al. Safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure. Transl Oncol. 2018;11:1155–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.tranon.2018.07.009.\nLi J, Chai X, Cao Y, et al. Intensity-modulated radiation therapy combined with concomitant temozolomide for brain metastases from lung adenocarcinoma. Oncol Lett. 2018;16:4285–90. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fol.2018.9171.\nStupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J of Med. 2005;352:987–96. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa043330.\nPellerino A, Soffietti R, Rudà R. Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. J Neurooncol. 2016;127:201–3. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11060-015-2016-6.\nAbolfotoh M, Tavanaiepour D, Hong C, et al. Primary calcified rhabdoid meningioma of the cranio-cervical junction: a case report and review of literature. J Craniovertebr Junction Spine. 2012;3:32–7. https:\u002F\u002Fdoi.org\u002F10.4103\u002F0974-8237.110127.\nAdeberg S, Hartmann C, Welzel T, et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas—clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83:859–64. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijrobp.2011.08.010.\nAdeberg S, Welzel T, Rieken S, et al. Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiat Oncol. 2011;6:117. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijrobp.2011.08.010.\nAizer AA, Arvold ND, Catalano P, et al. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neurooncol. 2014;16:1547–53. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fneuonc\u002Fnou098.\nAlbert A, Lee A, Vijayakumar S, et al. Adjuvant treatment of meningioma with stereotactic radiation surgery and hypofractionated stereotactic radiation surgery: patterns of care and survival in a large, hospital database. Adv Radiat Oncol. 2018;3:280–7. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.adro.2018.04.004.\nAnvari K, Hosseini S, Rahighi S, et al. Intracranial meningiomas: prognostic factors and treatment outcome in patients undergoing postoperative radiation therapy. Adv Biomed Res. 2016;5:83–83. https:\u002F\u002Fdoi.org\u002F10.4103\u002F2277-9175.182214.\nAskoxylakis V, Zabel-du Bois A, Schlegel W, et al. Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol. 2010;98:367–72. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11060-009-0084-1.\nBalasubramanian SK, Sharma M, Silva D, et al. Longitudinal experience with WHO grade III (anaplastic) meningiomas at a single institution. J Neurooncol. 2017;131:555–63.\nBoulle G, Bracci S, Hitchcock K, et al. Treatment of grade II–III intracranial meningioma with helical tomotherapy. J Clin Neurosci. 2019;59:190–6. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jocn.2018.10.073.\nBuglione M, De Bari B, Trevisan F, et al. Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol. 2014;31:866. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs12032-014-0866-y.\nCain SA, Smoll NR, Van Heerden J, et al. Atypical and malignant meningiomas: considerations for treatment and efficacy of radiotherapy. J Clin Neurosci. 2015;22:1742–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jocn.2015.03.054.\nChen WC, Hara J, Magill ST, et al. Salvage therapy outcomes for atypical meningioma. J Neurooncol. 2018;138:425–33. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11060-018-2813-9.\nChoi Y, Lim DH, Yu JI, et al. Prognostic value of Ki-67 labeling index and postoperative radiotherapy in WHO grade II meningioma. Am J Clin Oncol. 2018;41:18–23.\nChung LK, Mathur I, Lagman C, et al. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy in benign meningioma. J Clin Neurosci. 2017;36:1–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jocn.2016.10.009.\nDetti B, Scoccianti S, Di Cataldo V, et al. Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients. J Neurooncol. 2013;115:421–7. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11060-013-1239-7.\nGraffeo CS, Leeper HE, Perry A, et al. Revisiting adjuvant radiotherapy after gross total resection of world health organization grade II meningioma. World Neurosurg. 2017;103:655–63. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.wneu.2017.04.095.\nHammouche S, Clark S, Wong AHL, et al. Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment. Acta Neurochir. 2014;156:1475–81. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00701-014-2156-z.\nJenkinson MD, Waqar M, Farah JO, et al. Early adjuvant radiotherapy in the treatment of atypical meningioma. J Clin Neurosci. 2016;28:87–92. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jocn.2015.09.021.\nKumar N, Kumar R, Khosla D, et al. Survival and failure patterns in atypical and anaplastic meningiomas: a single-center experience of surgery and postoperative radiotherapy. J Cancer Res Ther. 2015;11:735.\nLee KD, DePowell JJ, Air EL, et al. Atypical meningiomas: is postoperative radiotherapy indicated? Neurosurg Focus. 2013;35:E15. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2013.9.Focus13325.\nMasalha W, Heiland DH, Delev D, et al. Survival and prognostic predictors of anaplastic meningiomas. World Neurosurg. 2019;131:e321–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.wneu.2019.07.148.\nMasalha W, Heiland DH, Franco P, et al. Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy. J Neurooncol. 2018;136:147–54. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11060-017-2634-2.\nOnodera S, Aoyama H, Katoh N, et al. Long-term outcomes of fractionated stereotactic radiotherapy for intracranial skull base benign meningiomas in single institution. Jpn J Clin Oncol. 2011;41:462–8.\nPant S, Tonse R, Kannan S, et al. Impact of timing of radiation therapy on outcomes in atypical meningioma: a clinical audit. Pract Radiat Oncol. 2018;8:e275–84. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prro.2018.01.010.\nPress R, Prabhu R, Appin C, et al. Patterns of failure for grade 2\u002F3 meningioma treated with reduced margin intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:S158.\nShakir SI, Souhami L, Petrecca K, et al. Prognostic factors for progression in atypical meningioma. J Neurosurg. 2018;129:1240. https:\u002F\u002Fdoi.org\u002F10.3171\u002F2017.6.Jns17120.\nSun SQ, Cai C, Murphy RKJ, et al. Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurg. 2014;75:356–63. https:\u002F\u002Fdoi.org\u002F10.1227\u002Fneu.0000000000000462.\nSun SQ, Kim AH, Cai C, et al. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurg. 2014;75:347–55. https:\u002F\u002Fdoi.org\u002F10.1227\u002Fneu.0000000000000461.\nSoldà F, Wharram B, De Ieso PB, et al. Long-term efficacy of fractionated radiotherapy for benign meningiomas. Radiother Oncol. 2013;109:330–4. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.radonc.2013.10.006.\nTanzler E, Morris CG, Kirwan JM, et al. Outcomes of WHO grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:508–13. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijrobp.2009.11.032.\nvan Alkemade H, de Leau M, Dieleman EMT, et al. Impaired survival and long-term neurological problems in benign meningioma. Neurooncol. 2012;14:658–66. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fneuonc\u002Fnos013.\nWeber DC, Ares C, Villa S, et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042–26042). Radiother Oncol. 2018;128:260–5. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.radonc.2018.06.018.\nZhi M, Girvigian MR, Miller MJ, et al. Long-term outcomes of newly diagnosed resected atypical meningiomas and the role of adjuvant radiotherapy. World Neurosurg. 2019;122:e1153–61. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.wneu.2018.11.006.",{"EN":1375},"High-grade and recurrent meningiomas are often treatment resistant and pose a therapeutic challenge after surgical and radiation therapy (RT) failure. Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment. Thus, we investigated the potential efficacy of concomitant RT plus TMZ compared to historical controls of just RT used in the treatment of high-grade and recurrent meningiomas. We performed a retrospective analysis of patients with meningioma treated at the University of Colorado with TMZ chemoradiation. Progression free survival (PFS) and overall survival (OS) were calculated from the start of chemoradiation to local recurrence or death, respectively. Eleven patients (12 tumors) were treated with chemoradiation with a median follow-up of 41.5 months. There were two WHO grade 1, eight grade 2 and two grade 3 meningiomas. Three patients died during the follow-up period—one being disease related (11.1%). Two patients had meningioma recurrence—at 2.3 months (WHO grade 3), and 5.4 years (WHO grade 2). Three-year OS and PFS for grade 2 meningiomas were each 88%. Historical controls demonstrate a 3-year median OS and PFS of 83% and 75.8%, respectively. Treatment options are limited for meningiomas after local failure. In this study, TMZ chemoradiation demonstrated no significant difference in PFS and OS in the treatment of grade 2 meningiomas compared to historic controls. Further study is warranted to find novel methods for the treatment of malignant and recurrent meningiomas.",{"EN":1377},"Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review",{"VOID":1379},"10.1186\u002Fs12885-022-09340-7","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-022-09340-7",[1382,1397,1409,1421,1436],{"id":1383,"sortIndex":115,"researcher":20,"roles":1384,"affiliations":1385,"properties":1394},"432f4f48-27c8-4e34-aed1-906228238161",[186],[1386],{"id":20,"sortIndex":21,"affiliation":1387,"properties":20},{"id":1388,"createTime":1389,"updateTime":1389,"relativeEntities":1390,"slug":20,"properties":1391,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"c039137a-13fe-4eb9-8203-fefea942a36b","2023-12-06T19:06:52.817+00:00",[],{"title":1392},{"VI":1393},"Department of Neurosurgery, University of Colorado School of Medicine, Aurora, USA",{"title":1395},{"VI":1396},"Timothy H. Ung",{"id":1398,"sortIndex":224,"researcher":20,"roles":1399,"affiliations":1400,"properties":1406},"fd94239f-2392-4b0a-b3c8-5113638182b7",[186],[1401],{"id":20,"sortIndex":21,"affiliation":1402,"properties":20},{"id":1388,"createTime":1389,"updateTime":1389,"relativeEntities":1403,"slug":20,"properties":1404,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1405},{"VI":1393},{"title":1407},{"VI":1408},"Kevin O. Lillehei",{"id":1410,"sortIndex":21,"researcher":20,"roles":1411,"affiliations":1412,"properties":1418},"7ed5b4c2-5ae5-4372-adbd-98b35930a6f7",[186],[1413],{"id":20,"sortIndex":21,"affiliation":1414,"properties":20},{"id":1388,"createTime":1389,"updateTime":1389,"relativeEntities":1415,"slug":20,"properties":1416,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1417},{"VI":1393},{"title":1419},{"VI":1420},"Katherine Belanger",{"id":1422,"sortIndex":211,"researcher":20,"roles":1423,"affiliations":1424,"properties":1433},"b82a80b1-1b86-419f-bdcf-96060c8e11b8",[186],[1425],{"id":20,"sortIndex":21,"affiliation":1426,"properties":20},{"id":1427,"createTime":1428,"updateTime":1428,"relativeEntities":1429,"slug":20,"properties":1430,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"f2aacc6e-00d5-4b18-a29f-d33dbee8c48f","2024-01-04T02:32:19.028+00:00",[],{"title":1431},{"VI":1432},"Department of Neurology, University of Colorado School of Medicine, Aurora, USA",{"title":1434},{"VI":1435},"Denise Damek",{"id":1437,"sortIndex":184,"researcher":20,"roles":1438,"affiliations":1439,"properties":1445},"c15a95c4-f7a6-45a8-a3da-5e38dd34086f",[186],[1440],{"id":20,"sortIndex":21,"affiliation":1441,"properties":20},{"id":1388,"createTime":1389,"updateTime":1389,"relativeEntities":1442,"slug":20,"properties":1443,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1444},{"VI":1393},{"title":1446},{"VI":1447},"D. Ryan Ormond",{"url":1380,"publisher":1449,"properties":1477},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1450,"slug":10,"properties":1451,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1455,"manageAffiliations":1456,"indexDatabases":1457,"url":20,"thumbnailPath":20,"statistic":1472,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":1452,"title":1453,"url":1454},{"VOID":13},{"EN":15},{"VOID":17},[],[],[1458,1465],{"id":72,"indexDatabase":1459,"url":87,"indexYears":20,"academicFieldIds":1464,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":1460,"label":1461,"description":1462,"key":83,"publicationTags":1463,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":1466,"url":104,"indexYears":105,"academicFieldIds":1471,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":1467,"label":1468,"description":1469,"key":101,"publicationTags":1470,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":1473,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":1474,"totalCitation":142,"totalCitationByYear":1475,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":1476,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":1478,"pages":1479},{"VOID":1360},{"VOID":1480},"1-6","2022-04-07",{"id":1483,"createTime":1484,"updateTime":1485,"relativeEntities":1486,"slug":1487,"properties":1488,"entityType":177,"verifyStatus":178,"verifyTime":1485,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1497,"fullTextUrl":20,"authors":1498,"publicationType":262,"publisherRelationship":1630,"citationCount":20,"citationInfo":20,"publishDate":1662,"publishYear":1204,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"9674c58f-f5b9-4875-99c3-0b6e12aa9b38","2024-01-10T11:49:03.987+00:00","2025-01-11T23:59:00.101+00:00",[],"Does-anti-p53-antibody-status-predict-for-clinical-outcomes-in-metastatic-colorectal-cancer-patients-treated-with-fluoropyrimidine-oxaliplatin-plus-bevacizumab-as-first-line-chemotherapy-",{"references":1489,"abstract":1491,"title":1493,"doi":1495},{"VOID":1490},"Vogelstein B, Fearton ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1998;319:525–32.\nShimada H, Okazumi S, Takeda A, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al. Presence of serum p53 antibodies is associated with decreased in vitro chemo sensitivity in patients with esophageal cancer. Surg Today. 2001;31:591–96.\nMollevi DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastasis undergoing surgical resection. Carcinogenesis. 2007;28:1241–47.\nPopat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Annals of Oncology. 2006;17:1810–17.\nLubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995;1(12):1463–69.\nBlanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin V, Hennequin C, et al. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Cancer. 2012;12:119.\nBazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, et al. Specific TP53 and\u002For Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol. 2005;16:Suppl 4:50–55.\nShimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1085 patients with various cancers. A multi-institutional analysis by Japan p53 Antibody Research Group. Cancer. 2003;97:682–89.\nFukushima Y, Yanaka S, Murakami K, et al. High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2011;38:1825–35.\nSuppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer. World J Gastroenterol. 2013;19(29):4651–70.\nWestra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5635–43.\nAngelopoulou K, Stratis M, Diamandis EP. Humoral immuneresponse against p53 protein in patients with colorectalcarcinoma. Int J Cancer. 1997;70:46–51.\nRusso A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.\nLan YT, Chang SC, Li AF, Lin TC, Chen WS, Jiang JK, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007;22(5):499–506.\nTriantafyllou K, Paspatis GA, Zizi A, Papatheodoridis GV, Tzouvala M, Chlouverakis GJ, et al. p53 protein accumulation and colonic adenoma recurrence. Eur J Gastroenterol Hepatol 1999;11(5):547–52.\nWang Q, Zhao P, Hu Y, Yang G, et al. Prognostic significance of P53 protein expression in patients with colorectal adenocarcinoma. Hua Xi Yi Ke Da Xue Xue Bao. 1998;29(2):182–84.\nHu J, Wang Z, Jiang Y. Relations between p53 and p185 expression and prognosis of patients with colon cancers. Zhonghua Zhong Liu Za Zhi. 1996;18(4):247–49.\nGrewal H, Guillem JG, Klimstra DS, Cohen AM, et al. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum. 1995;38(11):1176–81.\nBouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer. 2000;36(8):1008–15.\nSamowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99(4):597–602.\nChang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK, et al. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int J Colorectal Dis. 2009;24(6):623–28.\nKressner U, Glimelius B, Bergström R, Påhlman L, Larsson A, Lindmark G, et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer. 1998;77(11):1848–851.\nSuppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J, et al. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis. 2008;23(6):595–600.\nKressner U, Lindmark G, Gerdin B, Påhlman L, Glimelius B, et al. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996;16(2):951–57.\nZaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.\nAhn MJ, Choi JH, Oh HS, Lee YY, Kim IS, Choi IY, et al. Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy. Cancer Res Treat. 2005;37(4):216–22.\nBerglund A, Edler D, Molin D, Nordlinder H, Graf W, Glimelius B, et al. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res. 2002;22(6B):3653–59.\nInce WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of K-RAS, B-RAF, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97(13):981–89.\nMolleví DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis. 2007;28(6):1241–46.\nRosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer. 2001;95(3):162–67.\nOden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100(8):1330–35.",{"EN":1492},"TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 antibody positivity. This study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy. Ninety patients treated with fluoropyrimidine, oxaliplatin plus bevacizumab as first-line chemotherapy were enrolled, including 70 whose KRAS genotype was revealed at the beginning of treatment. Before chemotherapy initiation, the serum p53 antibody level was quantified by enzyme-linked immunosorbent assay using MESACUP® anti-p53 test kits. The cutoff value for positivity was 1.3 U\u002FmL, as calculated previously. The KRAS genotype of the tumor samples was analyzed using the Luminex® assay. Overall response rates of Response Evaluation Criteria in Solid Tumors criteria were 77.7 % (42\u002F54) in anti-p53–negative patients and 69.4 % (25\u002F36) in anti-p53–positive patients. The odds ratio was 1.07. Median overall survival was 36.1 months in the anti-p53–positive patients, and not available in the anti-p53–negative patients (hazard ratio, 0.81; 95 % confidence interval, 0.37–1.77; P = 0.61). The corresponding values for median progression-free survival were 13.3 months and 14.6 months (hazard ratio, 0.69; 95 % confidence interval, 0.41–1.17; P = 0.17), respectively. Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.",{"EN":1494},"Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?",{"VOID":1496},"10.1186\u002Fs12885-015-1751-6","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-015-1751-6",[1499,1514,1526,1541,1558,1570,1582,1594,1606,1618],{"id":1500,"sortIndex":156,"researcher":20,"roles":1501,"affiliations":1502,"properties":1511},"63275673-9636-4e94-9e83-e8767672fdc5",[186],[1503],{"id":20,"sortIndex":21,"affiliation":1504,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1507,"slug":20,"properties":1508,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"89a746fa-de2a-475e-9a0b-aeedaaa4c130","2024-01-10T11:49:04.136+00:00",[],{"title":1509},{"VI":1510},"Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan",{"title":1512},{"VI":1513},"Keisho Chin",{"id":1515,"sortIndex":373,"researcher":20,"roles":1516,"affiliations":1517,"properties":1523},"6e335775-0729-4ada-9f81-7c3729f6d8e6",[186],[1518],{"id":20,"sortIndex":21,"affiliation":1519,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1520,"slug":20,"properties":1521,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1522},{"VI":1510},{"title":1524},{"VI":1525},"Masato Ozaka",{"id":1527,"sortIndex":184,"researcher":20,"roles":1528,"affiliations":1529,"properties":1538},"1690bc81-913f-40a2-b982-7c62a7723126",[186],[1530],{"id":20,"sortIndex":21,"affiliation":1531,"properties":20},{"id":1532,"createTime":1533,"updateTime":1533,"relativeEntities":1534,"slug":20,"properties":1535,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"b0423f5a-75b2-4886-9a09-1347cdd3a798","2024-01-10T11:49:04.072+00:00",[],{"title":1536},{"VI":1537},"Medical Department of Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan",{"title":1539},{"VI":1540},"Mariko Ogura",{"id":1542,"sortIndex":649,"researcher":20,"roles":1543,"affiliations":1544,"properties":1555},"4db507ef-6046-46eb-93ae-70f8e1024a8b",[186],[1545],{"id":20,"sortIndex":21,"affiliation":1546,"properties":20},{"id":1547,"createTime":1548,"updateTime":1549,"relativeEntities":1550,"slug":1551,"properties":1552,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"0bcaa7db-e7ac-4ad3-a49b-4d7025d35ea7","2023-12-17T21:10:36.212+00:00","2025-06-12T00:38:51.097+00:00",[],"Department-of-Pathology-The-Cancer-Institute-Hospital-Japanese-Foundation-for-Cancer-Research-Tokyo-Japan",{"title":1553},{"VI":1554},"Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan",{"title":1556},{"VI":1557},"Noriko Yamamoto",{"id":1559,"sortIndex":211,"researcher":20,"roles":1560,"affiliations":1561,"properties":1567},"d6cdaf95-8ca9-49ec-810c-d12dbeb95892",[186],[1562],{"id":20,"sortIndex":21,"affiliation":1563,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1564,"slug":20,"properties":1565,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1566},{"VI":1510},{"title":1568},{"VI":1569},"Mitsukuni Suenaga",{"id":1571,"sortIndex":114,"researcher":20,"roles":1572,"affiliations":1573,"properties":1579},"835c9fd4-fd90-420e-bdee-ac2a2cad034e",[186],[1574],{"id":20,"sortIndex":21,"affiliation":1575,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1576,"slug":20,"properties":1577,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1578},{"VI":1510},{"title":1580},{"VI":1581},"Satoshi Matsusaka",{"id":1583,"sortIndex":115,"researcher":20,"roles":1584,"affiliations":1585,"properties":1591},"d00877b4-e05a-42e3-b4d3-b7f9b6c5bb63",[186],[1586],{"id":20,"sortIndex":21,"affiliation":1587,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1588,"slug":20,"properties":1589,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1590},{"VI":1510},{"title":1592},{"VI":1593},"Eiji Shinozaki",{"id":1595,"sortIndex":224,"researcher":20,"roles":1596,"affiliations":1597,"properties":1603},"89190c06-4d92-47ce-8401-959d5c830228",[186],[1598],{"id":20,"sortIndex":21,"affiliation":1599,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1600,"slug":20,"properties":1601,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1602},{"VI":1510},{"title":1604},{"VI":1605},"Yosuke Kumekawa",{"id":1607,"sortIndex":21,"researcher":20,"roles":1608,"affiliations":1609,"properties":1615},"8d380cc4-b5e5-4843-b4cc-6954479c3602",[186],[1610],{"id":20,"sortIndex":21,"affiliation":1611,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1612,"slug":20,"properties":1613,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1614},{"VI":1510},{"title":1616},{"VI":1617},"Hiroki Osumi",{"id":1619,"sortIndex":57,"researcher":20,"roles":1620,"affiliations":1621,"properties":1627},"ba75347b-f7e1-4762-8b37-ab24c6cb896e",[186],[1622],{"id":20,"sortIndex":21,"affiliation":1623,"properties":20},{"id":1505,"createTime":1506,"updateTime":1506,"relativeEntities":1624,"slug":20,"properties":1625,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1626},{"VI":1510},{"title":1628},{"VI":1629},"Nobuyuki Mizunuma",{"url":1497,"publisher":1631,"properties":1659},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1632,"slug":10,"properties":1633,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1637,"manageAffiliations":1638,"indexDatabases":1639,"url":20,"thumbnailPath":20,"statistic":1654,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":1634,"title":1635,"url":1636},{"VOID":13},{"EN":15},{"VOID":17},[],[],[1640,1647],{"id":72,"indexDatabase":1641,"url":87,"indexYears":20,"academicFieldIds":1646,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":1642,"label":1643,"description":1644,"key":83,"publicationTags":1645,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":1648,"url":104,"indexYears":105,"academicFieldIds":1653,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":1649,"label":1650,"description":1651,"key":101,"publicationTags":1652,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":1655,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":1656,"totalCitation":142,"totalCitationByYear":1657,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":1658,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":1660,"pages":1661},{"VOID":1201},{"VOID":296},"2015-10-21",{"id":1664,"createTime":1665,"updateTime":1665,"relativeEntities":1666,"slug":20,"properties":1667,"entityType":177,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1676,"fullTextUrl":20,"authors":1677,"publicationType":262,"publisherRelationship":1898,"citationCount":20,"citationInfo":20,"publishDate":1931,"publishYear":1932,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"88098c53-a7a1-4a6f-b90f-d50fa2f17986","2024-01-27T23:58:48.946+00:00",[],{"references":1668,"abstract":1670,"title":1672,"doi":1674},{"VOID":1669},"von Hoff K, Hinkes B, Dannenmann-Stern E, von Bueren AO, Warmuth-Metz M, Soerensen N, Emser A, Zwiener I, Schlegel PG, Kuehl J, et al. Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT\u002FRT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer. 2011;57(6):978–85.\nLee JY, Kim IK, Phi JH, Wang KC, Cho BK, Park SH, Ahn HS, Kim IH, Kim SK. Atypical teratoid\u002Frhabdoid tumors: the need for more active therapeutic measures in younger patients. J Neuro-Oncol. 2012;107(2):413–9.\nChi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27(3):385–9.\nLafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer S, Wilson B, Jabado N, Scheinemann K, Eisenstat D, Fryer C, et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric brain tumour consortium experience. Eur J Cancer. 2012;48(3):353–9.\nHasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, Oyen F, Nagel I, Richter J, Bartelheim K, Kordes U, et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid\u002Frhabdoid tumors. Genes Chromosomes Cancer. 2013;52(2):185–90.\nWilson BG, Roberts CW. SWI\u002FSNF nucleosome remodellers and cancer. Nature Rev Cancer. 2011;11(7):481–92.\nHoell JI, Gombert M, Bartenhagen C, Ginzel S, Husemann P, Felsberg J, Reifenberger G, Eggert A, Dugas M, Schonberger S, et al. Whole-genome paired-end analysis confirms remarkable genomic stability of atypical teratoid\u002Frhabdoid tumors. Genes Chromosomes Cancer. 2013;52(10):983–5.\nJohann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, et al. Atypical Teratoid\u002FRhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell. 2016;29(3):379–93.\nLawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.\nTorchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, et al. Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS Rhabdoid tumors. Cancer Cell. 2016;30(6):891–908.\nTorchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, Ra YS, Ho KC, Chan TS, Sin-Chan P, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 2015;16(5):569–82.\nBirks DK, Donson AM, Patel PR, Sufit A, Algar EM, Dunham C, Kleinschmidt-DeMasters BK, Handler MH, Vibhakar R, Foreman NK. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. Pediatr Blood Cancer. 2013;60(7):1095–102.\nGuidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, Smith TW, Imbalzano AN, Jones SN. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol. 2001;21(10):3598–603.\nNg JM, Martinez D, Marsh ED, Zhang Z, Rappaport E, Santi M, Curran T. Generation of a mouse model of atypical teratoid\u002Frhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. Cancer Res. 2015;75(21):4629–39.\nKieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012;59(7):1155–7.\nLee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV. Aurora a is a repressed effector target of the chromatin remodeling protein INI1\u002FhSNF5 required for rhabdoid tumor cell survival. Cancer Res. 2011;71(9):3225–35.\nHelming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI\u002FSNF complexes in cancer. Cancer Cell. 2014;26(3):309–17.\nAlimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro-Oncology. 2013;15(2):149–60.\nTsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV. Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci U S A. 2005;102(34):12129–34.\nZhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV. Cell cycle arrest and repression of cyclin D1 transcription by INI1\u002FhSNF5. Mol Cell Biol. 2002;22(16):5975–88.\nKnutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922–7.\nTolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ, et al. Swi\u002FSnf chromatin remodeling\u002Ftumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci U S A. 2013;110(25):10165–70.\nAbecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.\nCingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6(2):80–92.\nLi J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG, Gorringe KL. CONTRA: copy number analysis for targeted resequencing. Bioinformatics. 2012;28(10):1307–13.\nTrapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–11.\nAnders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.\nIsakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A. 2005;102(49):17745–50.\nVan Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107(39):16910–5.\nSubramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.\nWarde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–20.\nChoi SA, Kim SK, Lee JY, Wang KC, Lee C, Phi JH. LIN28B is highly expressed in atypical teratoid\u002Frhabdoid tumor (AT\u002FRT) and suppressed through the restoration of SMARCB1. Cancer Cell Int. 2016;16:32.\nChoi SA, Choi JW, Wang KC, Phi JH, Lee JY, Park KD, Eum D, Park SH, Kim IH, Kim SK. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid\u002Frhabdoid tumors. Neuro-Oncology. 2015;17(6):810–21.\nBiegel JA, Busse TM, Weissman BE. SWI\u002FSNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet. 2014;166C(3):350–66.\nKadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI\u002FSNF complexes identifies extensive roles in human malignancy. Nature Genet. 2013;45(6):592–601.\nLee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, Lawrence MS, Auclair D, Mora J, Golub TR, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122(8):2983–8.\nFruhwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Atypical teratoid\u002Frhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro-Oncology. 2016;18(6):764–78.\nKia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI\u002FSNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol. 2008;28(10):3457–64.\nSmith ME, Cimica V, Chinni S, Jana S, Koba W, Yang Z, Fine E, Zagzag D, Montagna C, Kalpana GV. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1. Proc Natl Acad Sci U S A. 2011;108(1):319–24.\nGrisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493–505.\nVenneti S, Le P, Martinez D, Eaton KW, Shyam N, Jordan-Sciutto KL, Pawel B, Biegel JA, Judkins AR. p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors. J Neuropathol Exp Neurol. 2011;70(7):596–609.\nChai J, Charboneau AL, Betz BL, Weissman BE. Loss of the hSNF5 gene concomitantly inactivates p21CIP\u002FWAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 2005;65(22):10192–8.\nOruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, Vries RG, Hoeben RC, Verrijzer CP. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem. 2004;279(5):3807–16.\nBetz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5\u002FINI1\u002FBAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 2002;21(34):5193–203.\nBoon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001;20(6):1383–93.\nZeller KI, Haggerty TJ, Barrett JF, Guo Q, Wonsey DR, Dang CV. Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem. 2001;276(51):48285–91.\nJiang PS, Yung BY. Down-regulation of nucleophosmin\u002FB23 mRNA delays the entry of cells into mitosis. Biochem Biophys Res Commun. 1999;257(3):865–70.\nBernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, et al. Functional proteomic analysis of melanoma progression. Cancer Res. 2003;63(20):6716–25.\nChen J, Sun J, Yang L, Yan Y, Shi W, Shi J, Huang Q, Chen J, Lan Q. Upregulation of B23 promotes tumor cell proliferation and predicts poor prognosis in glioma. Biochem Biophys Res Commun. 2015;466(1):124–30.\nLin CY, Chao A, Wang TH, Lee LY, Yang LY, Tsai CL, Wang HS, Lai CH. Nucleophosmin\u002FB23 is a negative regulator of estrogen receptor alpha expression via AP2gamma in endometrial cancer cells. Oncotarget. 2016;7(37):60038–52.\nNozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin\u002FB23 in normal and neoplastic colorectal mucosa. J Pathol. 1996;178(1):48–52.\nShields LB, Gercel-Taylor C, Yashar CM, Wan TC, Katsanis WA, Spinnato JA, Taylor DD. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig. 1997;4(6):298–304.\nSubong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin\u002FB23. Prostate. 1999;39(4):298–304.\nTsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY. Association of nucleophosmin\u002FB23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin. 2008;29(3):364–70.\nZhou F, Chen E, You D, Song Y, Sun Z, Yue L. Both high expression of nucleophosmin\u002FB23 and CRM1 predicts poorer prognosis in human gastric cancer. APMIS. 2016;124(12):1046–105.\nQi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008;27(30):4210–20.\nBalusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 2011;118(11):3096–106.\nDi Matteo A, Franceschini M, Chiarella S, Rocchio S, Travaglini-Allocatelli C, Federici L. Molecules that target nucleophosmin for cancer treatment: an update. Oncotarget. 2016;7(28):44821–40.\nLindstrom MS, Zhang Y. B23 and ARF: friends or foes? Cell Biochem Biophys. 2006;46(1):79–90.\nMaiguel DA, Jones L, Chakravarty D, Yang C, Carrier F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol. 2004;24(9):3703–11.",{"EN":1671},"Atypical teratoid\u002Frhabdoid tumors (AT\u002FRTs) are highly malignant brain tumors with inactivation of the SMARCB1 gene, which play a critical role in genomic transcriptional control. In this study, we analyzed the genomic and transcriptomic profiles of human AT\u002FRTs to discover new druggable targets. Multiplanar sequencing analyses, including whole exome sequencing (WES), single nucleotide polymorphism (SNP) arrays, array comparative genomic hybridization (aCGH), and whole transcriptome sequencing (RNA-Seq), were performed on 4 AT\u002FRT tissues. Validation of a druggable target was conducted using AT\u002FRT cell lines. WES revealed that the AT\u002FRT genome is extremely stable except for the inactivation of SMARCB1. However, we identified 897 significantly upregulated genes and 523 significantly downregulated genes identified using RNA-Seq, indicating that the transcriptional profiles of the AT\u002FRT tissues changed substantially. Gene set enrichment assays revealed genes related to the canonical pathways of cancers, and nucleophosmin (NPM1) was the most significantly upregulated gene in the AT\u002FRT samples. An NPM1 inhibitor (NSC348884) effectively suppressed the viability of 7 AT\u002FRT cell lines. Network analyses showed that genes associated with NPM1 are mainly involved in cell cycle regulation. Upon treatment with an NPM1 inhibitor, cell cycle arrest at G1 phase was observed in AT\u002FRT cells. We propose that NPM1 is a novel therapeutic target for AT\u002FRTs.",{"EN":1673},"NPM1 as a potential therapeutic target for atypical teratoid\u002Frhabdoid tumors",{"VOID":1675},"10.1186\u002Fs12885-019-6044-z","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-019-6044-z",[1678,1715,1734,1749,1764,1783,1795,1810,1825,1844,1869,1886],{"id":1679,"sortIndex":156,"researcher":20,"roles":1680,"affiliations":1681,"properties":1712},"422a802b-b58b-4c08-8842-31a5b0cbf442",[186],[1682,1690,1700],{"id":20,"sortIndex":21,"affiliation":1683,"properties":20},{"id":1684,"createTime":1685,"updateTime":1685,"relativeEntities":1686,"slug":20,"properties":1687,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ca1c431e-c845-404e-8b5a-d61e46a641c5","2023-12-07T12:34:31.869+00:00",[],{"title":1688},{"VI":1689},"Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience Center, Seoul National University Children’s Hospital, Seoul, Republic of Korea",{"id":1691,"sortIndex":211,"affiliation":1692,"properties":1699},"1fb0093b-819f-486d-9592-83596db6ad5f",{"id":1693,"createTime":1694,"updateTime":1694,"relativeEntities":1695,"slug":20,"properties":1696,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"2aad25ff-93dd-46b4-b29a-029a2db8ab9e","2024-01-03T06:33:26.903+00:00",[],{"title":1697},{"VI":1698},"Department of Anatomy, Seoul National University College of Medicine, Seoul, Republic of Korea",{},{"id":1701,"sortIndex":115,"affiliation":1702,"properties":1711},"2ea0ffa6-9761-4de7-815d-a4d1e08e097a",{"id":1703,"createTime":1704,"updateTime":1705,"relativeEntities":1706,"slug":1707,"properties":1708,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"2ef86e1e-8ac4-485c-bfb7-7d51fab0b2f2","2024-01-27T13:47:43.590+00:00","2024-12-29T17:53:40.658+00:00",[],"Department-of-Neurosurgery-Seoul-National-University-College-of-Medicine-Seoul-Republic-of-Korea",{"title":1709},{"VI":1710},"Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea",{},{"title":1713},{"VI":1714},"Ji Yeoun Lee",{"id":1716,"sortIndex":57,"researcher":20,"roles":1717,"affiliations":1718,"properties":1731},"224e9257-37c2-455c-a76a-37ab9f18aed4",[186],[1719,1724],{"id":20,"sortIndex":21,"affiliation":1720,"properties":20},{"id":1684,"createTime":1685,"updateTime":1685,"relativeEntities":1721,"slug":20,"properties":1722,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1723},{"VI":1689},{"id":1725,"sortIndex":115,"affiliation":1726,"properties":1730},"85d221c9-d4f4-4d4f-9c49-971ea17fd259",{"id":1703,"createTime":1704,"updateTime":1705,"relativeEntities":1727,"slug":1707,"properties":1728,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1729},{"VI":1710},{},{"title":1732},{"VI":1733},"Seung-Ki Kim",{"id":1735,"sortIndex":68,"researcher":20,"roles":1736,"affiliations":1737,"properties":1746},"297a3f07-2d97-4475-bee4-f22a094d90e7",[186],[1738],{"id":20,"sortIndex":21,"affiliation":1739,"properties":20},{"id":1740,"createTime":1741,"updateTime":1741,"relativeEntities":1742,"slug":20,"properties":1743,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"32ed790b-6e5a-4f7b-875c-a641f13ebef1","2024-02-08T20:42:19.016+00:00",[],{"title":1744},{"VI":1745},"Center for Precision Medicine, Seoul National University Hospital, Seoul, Republic of Korea",{"title":1747},{"VI":1748},"Hongseok Yun",{"id":1750,"sortIndex":224,"researcher":20,"roles":1751,"affiliations":1752,"properties":1761},"d2c9ad04-8b44-4b26-8100-d7482035f1e5",[186],[1753],{"id":20,"sortIndex":21,"affiliation":1754,"properties":20},{"id":1755,"createTime":1756,"updateTime":1756,"relativeEntities":1757,"slug":20,"properties":1758,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"7ebb776f-cf47-40f1-8133-3229727baca3","2024-01-27T23:58:48.957+00:00",[],{"title":1759},{"VI":1760},"Graduated, Department of Statistics, Seoul National University, Seoul, Republic of Korea",{"title":1762},{"VI":1763},"Seungmook Lee",{"id":1765,"sortIndex":21,"researcher":20,"roles":1766,"affiliations":1767,"properties":1780},"ddb12c5b-1e2a-4b63-b8b9-9090d22f45ee",[186],[1768,1773],{"id":20,"sortIndex":21,"affiliation":1769,"properties":20},{"id":1684,"createTime":1685,"updateTime":1685,"relativeEntities":1770,"slug":20,"properties":1771,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1772},{"VI":1689},{"id":1774,"sortIndex":115,"affiliation":1775,"properties":1779},"900f14f5-11cf-4a43-8daf-2ae6e6d7a96e",{"id":1703,"createTime":1704,"updateTime":1705,"relativeEntities":1776,"slug":1707,"properties":1777,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1778},{"VI":1710},{},{"title":1781},{"VI":1782},"Ji Hoon Phi",{"id":1784,"sortIndex":373,"researcher":20,"roles":1785,"affiliations":1786,"properties":1792},"08ad9ec2-826f-4b3a-b05f-50ffc2a76e3c",[186],[1787],{"id":20,"sortIndex":21,"affiliation":1788,"properties":20},{"id":1684,"createTime":1685,"updateTime":1685,"relativeEntities":1789,"slug":20,"properties":1790,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1791},{"VI":1689},{"title":1793},{"VI":1794},"Seung Ah Choi",{"id":1796,"sortIndex":115,"researcher":20,"roles":1797,"affiliations":1798,"properties":1807},"73240c32-1644-4d4c-aa90-8ac2acfc7f9e",[186],[1799],{"id":20,"sortIndex":21,"affiliation":1800,"properties":20},{"id":1801,"createTime":1802,"updateTime":1802,"relativeEntities":1803,"slug":20,"properties":1804,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"72e87f3d-b6b8-404b-8d80-55fdd86a79bd","2024-01-27T23:58:49.006+00:00",[],{"title":1805},{"VI":1806},"Genome opinion Co., Ltd. 7, Seongdong-gu, Republic of Korea",{"title":1808},{"VI":1809},"Choong-Hyun Sun",{"id":1811,"sortIndex":184,"researcher":20,"roles":1812,"affiliations":1813,"properties":1822},"042ce2ce-738a-400e-9e9b-10e72c086f37",[186],[1814],{"id":20,"sortIndex":21,"affiliation":1815,"properties":20},{"id":1816,"createTime":1817,"updateTime":1817,"relativeEntities":1818,"slug":20,"properties":1819,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"39739731-f246-4829-ad13-1313dab8d269","2024-01-27T23:58:49.036+00:00",[],{"title":1820},{"VI":1821},"SD Genomics, Seoul, Republic of Korea",{"title":1823},{"VI":1824},"Inho Park",{"id":1826,"sortIndex":649,"researcher":20,"roles":1827,"affiliations":1828,"properties":1841},"27965d6e-8ecc-4202-be2c-ef5f3cbf5c2d",[186],[1829,1834],{"id":20,"sortIndex":21,"affiliation":1830,"properties":20},{"id":1684,"createTime":1685,"updateTime":1685,"relativeEntities":1831,"slug":20,"properties":1832,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1833},{"VI":1689},{"id":1835,"sortIndex":115,"affiliation":1836,"properties":1840},"4f0dcccb-6894-4fd2-a90e-755a6d548893",{"id":1703,"createTime":1704,"updateTime":1705,"relativeEntities":1837,"slug":1707,"properties":1838,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1839},{"VI":1710},{},{"title":1842},{"VI":1843},"Kyu-Chang Wang",{"id":1845,"sortIndex":211,"researcher":20,"roles":1846,"affiliations":1847,"properties":1866},"182909ef-f6c3-47b8-ab9c-acb8767c29ad",[186],[1848,1858],{"id":1849,"sortIndex":115,"affiliation":1850,"properties":1857},"41be5a29-ec5f-4519-835d-c55c54fe67e9",{"id":1851,"createTime":1852,"updateTime":1852,"relativeEntities":1853,"slug":20,"properties":1854,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"1006ce8c-2d0d-4868-8796-c3ddbb2319af","2024-02-08T14:30:21.444+00:00",[],{"title":1855},{"VI":1856},"Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea",{},{"id":20,"sortIndex":21,"affiliation":1859,"properties":20},{"id":1860,"createTime":1861,"updateTime":1861,"relativeEntities":1862,"slug":20,"properties":1863,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"545ceffe-9037-47a5-806a-23a6d2776403","2023-12-14T09:26:07.142+00:00",[],{"title":1864},{"VI":1865},"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea",{"title":1867},{"VI":1868},"Se-Hoon Lee",{"id":1870,"sortIndex":114,"researcher":20,"roles":1871,"affiliations":1872,"properties":1883},"083015d3-9dcf-40c6-a04a-72be1f1bdcbd",[186],[1873],{"id":20,"sortIndex":21,"affiliation":1874,"properties":20},{"id":1875,"createTime":1876,"updateTime":1877,"relativeEntities":1878,"slug":1879,"properties":1880,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"0d7676c4-b451-462f-9b2a-be35fa4bc123","2024-01-15T12:29:51.449+00:00","2024-09-02T11:50:44.279+00:00",[],"Department-of-Pathology-Seoul-National-University-College-of-Medicine-Seoul-Republic-of-Korea",{"title":1881},{"VI":1882},"Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea",{"title":1884},{"VI":1885},"Sung-Hye Park",{"id":1887,"sortIndex":118,"researcher":20,"roles":1888,"affiliations":1889,"properties":1895},"590ef7b0-bc18-4e28-ad11-e83915c17dac",[186],[1890],{"id":20,"sortIndex":21,"affiliation":1891,"properties":20},{"id":1703,"createTime":1704,"updateTime":1705,"relativeEntities":1892,"slug":1707,"properties":1893,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1894},{"VI":1710},{"title":1896},{"VI":1897},"Chul-Kee Park",{"url":1676,"publisher":1899,"properties":1927},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1900,"slug":10,"properties":1901,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1905,"manageAffiliations":1906,"indexDatabases":1907,"url":20,"thumbnailPath":20,"statistic":1922,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":1902,"title":1903,"url":1904},{"VOID":13},{"EN":15},{"VOID":17},[],[],[1908,1915],{"id":72,"indexDatabase":1909,"url":87,"indexYears":20,"academicFieldIds":1914,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":1910,"label":1911,"description":1912,"key":83,"publicationTags":1913,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":1916,"url":104,"indexYears":105,"academicFieldIds":1921,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":1917,"label":1918,"description":1919,"key":101,"publicationTags":1920,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":1923,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":1924,"totalCitation":142,"totalCitationByYear":1925,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":1926,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":1928,"pages":1930},{"VOID":1929},"19",{"VOID":454},"2019-08-28",2019,{"id":1934,"createTime":1935,"updateTime":1936,"relativeEntities":1937,"slug":1938,"properties":1939,"entityType":177,"verifyStatus":178,"verifyTime":1936,"verifyNote":179,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1948,"fullTextUrl":20,"authors":1949,"publicationType":262,"publisherRelationship":2003,"citationCount":20,"citationInfo":20,"publishDate":2036,"publishYear":1932,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":299},"4c98b6ea-94b8-4b63-b548-d4c42e901ab6","2024-01-20T10:43:12.715+00:00","2025-02-26T23:58:44.920+00:00",[],"Could-aspirin-be-a-lifesaver-for-prostate-cancer-patients-in-prostate-cancer-specific-mortality-an-update-systematic-review-and-meta-analysis",{"references":1940,"abstract":1942,"title":1944,"doi":1946},{"VOID":1941},"Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002;3(3):166–74.\nLiu XH, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3):820–5.\nNash GF, et al. Platelets and cancer. Lancet Oncol. 2002;3(7):425–30.\nDowner MK, et al. Regular aspirin use and the risk of lethal prostate cancer in the physicians’ health study. Eur Urol. 2017;72(5):821–7.\nAssayag J, Pollak MN, Azoulay L. The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol. 2015;193(4):1220–5.\nLiu Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12(1):55.\nStang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses [J]. Eur J Epidemiol. 2010;25(9):603–5.\nHiggins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.\nBax L, et al. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 2009;169(2):249–55.\nSeagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ. 1997;316(7129):469–71.\nFlahavan EM, et al. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol. 2014;25(1):154–9.\nHurwitz LM, et al. Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomark Prev. 2019;28(3):563–9.\nChoe KS, et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30(28):3540–4.\nJacobs EJ, et al. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(33):3716–22.\nZhou CK, et al. Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts. Cancer Prev Res. 2017;10(7):410–20.\nRothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Mdica. 2010;377(9759):31–41.\nStock DC, et al. Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. Prostate. 2008;68(15):1655–65.\nVeitonmäki T, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. Prostate. 2015;75(13):1394–402.\nGupta S, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2015;42(1):73–8.\nYoshimura R, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2015;89(3):589–96.\nJacobs CD, et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther. 2014;15(6):699–706.\nFan LL, et al. Aspirin exposure and mortality risk among prostate cancer patients: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:1–15.",{"EN":1943},"Currently, clinical studies on the prognosis of prostate cancer (PC) taking aspirin were developing, but the precise mechanism of aspirin on tumor cells was still unclear. In addition, the conclusion that aspirin can improve the prognosis of PC patients continues to be controversial. Therefore, we collected comprehensive literatures and performed our study to explore the prognostic effect of aspirin on PC. A comprehensive literature search was performed in April 2019 based on PUBMED. EMBASE. Hazard Ratio (HR) as well as its 95% confidence interval (CIs) for prostate cancer specific mortality (PCSM) was extracted from eligible studies. A total of 10 eligible articles were used in our study. The pooled results showed that PC patients who used aspirin or taking aspirin did not have lower PCSM than those who had not used (HR =0.89, 95% CI: 0.73–1.08, P>0.05). In subgroup analysis, we found that taking aspirin before diagnosis of prostate cancer and taking aspirin after diagnosis of prostate cancer did not have significant association with PCSM. (pre-diagnostic use, HR = 0.88, 95% CI: 0.72–1.06; post-diagnosis use, HR = 0.88, 95% CI: 0.67–1.17). In addition, we found no significant association between aspirin use or its duration and the risk of PCSM. Another important result demonstrated that aspirin use was not associated with risk of PSCM in either high risk (T ≥ 3 and\u002For Gleason score ≥ 8) or low risk PC patients(low-risk PC, HR = 1.05, 95% CI: 0.81–1.35; high-risk PC, HR = 0.97, 95% CI: 0.75–1.24). Our results demonstrated that there was no significant association between aspirin use and the risk of PCSM. At the same time, the dosage and duration of aspirin use had no statistical influence on the risk of PCSM in high\u002Flow risk PC. Further studies are needed to confirm the findings.",{"EN":1945},"Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis",{"VOID":1947},"10.1186\u002Fs12885-019-6415-5","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-019-6415-5",[1950,1967,1979,1991],{"id":1951,"sortIndex":211,"researcher":20,"roles":1952,"affiliations":1953,"properties":1964},"1e7551ef-99fd-4b8a-b76b-ad64ec87718d",[186],[1954],{"id":20,"sortIndex":21,"affiliation":1955,"properties":20},{"id":1956,"createTime":1957,"updateTime":1958,"relativeEntities":1959,"slug":1960,"properties":1961,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"0ac16400-8b88-4514-952a-a3c98d23a034","2023-12-26T09:08:45.797+00:00","2025-06-11T23:39:02.388+00:00",[],"Department-of-Urology-The-Second-Hospital-of-Tianjin-Medical-University-Tianjin-China",{"title":1962},{"VI":1963},"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China",{"title":1965},{"VI":1966},"Tao Li",{"id":1968,"sortIndex":224,"researcher":20,"roles":1969,"affiliations":1970,"properties":1976},"6669168b-0cfa-403f-a159-b2863e4232c2",[186],[1971],{"id":20,"sortIndex":21,"affiliation":1972,"properties":20},{"id":1956,"createTime":1957,"updateTime":1958,"relativeEntities":1973,"slug":1960,"properties":1974,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1975},{"VI":1963},{"title":1977},{"VI":1978},"Ranlu Liu",{"id":1980,"sortIndex":21,"researcher":20,"roles":1981,"affiliations":1982,"properties":1988},"9a77cd6d-eaae-42cd-8ac8-14de7118eca5",[186],[1983],{"id":20,"sortIndex":21,"affiliation":1984,"properties":20},{"id":1956,"createTime":1957,"updateTime":1958,"relativeEntities":1985,"slug":1960,"properties":1986,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1987},{"VI":1963},{"title":1989},{"VI":1990},"Jiatong Zhou",{"id":1992,"sortIndex":115,"researcher":20,"roles":1993,"affiliations":1994,"properties":2000},"b6598120-c507-4b65-9f25-ceb5198f3173",[186],[1995],{"id":20,"sortIndex":21,"affiliation":1996,"properties":20},{"id":1956,"createTime":1957,"updateTime":1958,"relativeEntities":1997,"slug":1960,"properties":1998,"entityType":56,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":1999},{"VI":1963},{"title":2001},{"VI":2002},"Shuai Xia",{"url":1948,"publisher":2004,"properties":2032},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2005,"slug":10,"properties":2006,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2010,"manageAffiliations":2011,"indexDatabases":2012,"url":20,"thumbnailPath":20,"statistic":2027,"gsStatistic":20,"type":157,"analyzePriority":20},[],{"issn":2007,"title":2008,"url":2009},{"VOID":13},{"EN":15},{"VOID":17},[],[],[2013,2020],{"id":72,"indexDatabase":2014,"url":87,"indexYears":20,"academicFieldIds":2019,"indexDatabaseRanking":20},{"id":74,"createTime":75,"updateTime":76,"relativeEntities":2015,"label":2016,"description":2017,"key":83,"publicationTags":2018,"standard":20},[],{"EN":79,"VI":79},{"VI":81,"EN":82},[85,86],[89],{"id":91,"indexDatabase":2021,"url":104,"indexYears":105,"academicFieldIds":2026,"indexDatabaseRanking":110},{"id":93,"createTime":94,"updateTime":95,"relativeEntities":2022,"label":2023,"description":2024,"key":101,"publicationTags":2025,"standard":20},[],{"EN":98,"VI":98},{"EN":98,"VI":100},[103],[107,108,109],{"impactFactor":21,"impactFactorByYear":2028,"i10Index":114,"i10IndexLast5Year":115,"totalPublication":116,"totalPublicationByYear":2029,"totalCitation":142,"totalCitationByYear":2030,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":2031,"hindexLast5Year":156,"hindex":156},{"2009":113,"2010":21,"2016":21,"2017":21,"2018":113,"2019":21,"2020":21,"2021":21,"2022":21},{"2001":118,"2002":119,"2003":120,"2004":121,"2005":122,"2006":123,"2007":124,"2008":125,"2009":126,"2010":127,"2011":128,"2012":129,"2013":130,"2014":131,"2015":132,"2016":133,"2017":134,"2018":135,"2019":136,"2020":137,"2021":138,"2022":139,"2023":140,"2024":141},{"2006":144,"2008":145,"2015":146,"2016":144,"2017":57,"2018":147,"2019":148,"2020":118},{"2006":151,"2008":152,"2015":153,"2016":154,"2017":155,"2018":149,"2019":155,"2020":155},{"volume":2033,"pages":2034},{"VOID":1929},{"VOID":2035},"1-8","2019-12-05"]